content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="margin: 0"></P>
  
  <HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white">
  <TR>
      <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark One)</FONT></TD></TR>
  <TR>
      <TD STYLE="width: 7%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9746;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
  <TR>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the quarterly period ended June 30, 2017</B></FONT></TD></TR>
  <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the transition period from ______to______</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <B>000-54163</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR>
      <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NuLife Sciences, Inc.</B></FONT></TD></TR>
  <TR>
      <TD STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in&nbsp;its Charter)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
      <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 46%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-3876675</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of</P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employee Identification No.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2618 San Miguel, Suite 203</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Newport Beach, CA</B></P></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92660</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive office)</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;(949) 973-0684</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number,
  including area code)</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not Applicable</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>(Former Name, former address
  and former fiscal year, if changed since last report)</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
  Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and
  (2) has been subject to such filing requirements for the past 90 days.</FONT><BR>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&nbsp;</FONT> <FONT STYLE="font-family: MS Mincho; font-size: 9pt">&#9746;</FONT>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;No&nbsp;</FONT> <FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
  Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
  preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;</FONT>
  <FONT STYLE="font-family: MS Mincho; font-size: 9pt">&#9746;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;No&nbsp;</FONT>
  <FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of &ldquo;large accelerated filer,&rdquo;&nbsp;&ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule
  12b-2 of the Exchange Act:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 43%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
      <TD STYLE="width: 18%; line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 23%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
      <TD STYLE="width: 16%; line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer (Do not check if smaller reporting company)</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: MS Mincho; font-size: 9pt">&#9746;</FONT></TD></TR>
  </TABLE>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp; Yes&nbsp;</FONT><FONT STYLE="font-family: MS Mincho; font-size: 9pt">&#9746;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;No</FONT><FONT STYLE="font-family: MS Mincho; font-size: 10pt">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares
  outstanding of each of the issuer&rsquo;s classes of common stock as of the latest practicable date: As of July 31, 2017,
  there were <FONT STYLE="background-color: White">37,261,049</FONT> shares of $0.001 par value common stock, issued and
  outstanding.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  
  
  
  <HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <HR SIZE="4" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><A NAME="TableOfContents"></A>&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_001">PART I: FINANCIAL INFORMATION</A></B></FONT></TD>
      <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Item 1: Financial Statements</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Item 2: Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Item 3: Quantitative and Qualitative Disclosures about Market Risk</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Item 4: Controls and Procedures</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_006">PART II: OTHER INFORMATION</A></B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Item 1: Legal Proceedings</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Item 1A: Risk Factors</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Item 2: Unregistered Sales of Equity Securities and Use of Proceeds</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Item 3: Defaults Upon Senior Securities</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Item 4: Mine Safety Disclosures</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Item 5: Other Information</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Item 6: Exhibits</A></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_014">SIGNATURES</A></B></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_001"></A>PART I - FINANCIAL INFORMATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0"><B><A NAME="a_002"></A>ITEM 1.&nbsp; FINANCIAL STATEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>Consolidated Balance Sheets</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">June 30, 2017 (Unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-indent: 22.5pt">Cash</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">94,276</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,086</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,241</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.5in; padding-left: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">94,276</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,327</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,871</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">99,147</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,327</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">492,135</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">448,859</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Due to related parties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">52,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68,295</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,885</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Convertible note, current portion, net of debt discount of $94,958 and $-0-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,067</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">TOTAL CURRENT LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">745,497</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">636,244</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Convertible notes, net of debt discount and beneficial conversion feature of $34,794 and $91,480 and $516,100 and $-0-, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">184,106</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 22.5pt">Derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">283,800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">169,221</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">TOTAL LONG TERM LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">467,906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">177,766</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">TOTAL LIABILITIES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,213,403</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,010</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">STOCKHOLDERS&rsquo; EQUITY (DEFICIT):</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Preferred stock Series A, $0.001 par value; 15,000,000 shares authorized; 110,000 issued or outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Preferred stock Series B, $0.001 par value; 10,000,000 shares authorized; 10,000,000 issued or outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 22.5pt">Common stock, $0.001 par value; 475,000,000 shares authorized; 31,085,800 shares issued and outstanding respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,086</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,086</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 22.5pt">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,732,578</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">392,739</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 22.5pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,888,030</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,211,508</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,114,256</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(787,683</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">99,147</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,327</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: justify">Share and per share amounts
  have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>Consolidated Statements
  of Operations</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>For the Three and Nine
  Months Ended June 30, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD COLSPAN="7" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended June 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD COLSPAN="7" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended June 30,</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gross Profit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expense:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative expenses</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(199,964</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(51,228</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,433,027</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(228,637</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total operating expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(199,964</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(51,228</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,433,027</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(228,637</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(199,964</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,433,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(228,637</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(84,989</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,699</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(204,583</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,991</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss on change in fair value of derivative and derivative expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42,903</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(39,579</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before provision for income tax</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(327,854</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(53,927</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,676,522</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(235,628</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(327,854</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(53,927</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,676,522</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(235,628</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.12</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,085,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,085,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,085,800</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,634,561</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: justify">Share and per share amounts
  have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>NuLife Sciences, Inc.
  (fka &ldquo;SmooFi, Inc.&rdquo;)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consolidated Statement of Cash Flows</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>For the Nine Months Ended
  June 30, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOW FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,676,522</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">(235,628</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">81,173</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gain on change in fair value of derivative and derivative expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">114,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,700,654</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,098</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Bad debt on note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,904</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,165</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Note receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(663</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,437</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,871</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">57,026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,925</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Due to related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">134,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accrued interest payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,410</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,417</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Cash Used in Operating Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(669,810</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,260</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOW USED BY INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deposit on farm property</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loan to sellers of farm property</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(31,400</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net Cash Used by Investing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(56,400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOW FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loan proceeds</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Proceeds from the issuance of convertible notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">763,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Cash Provided by Financing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">763,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">74,500</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CHANGE IN CASH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93,190</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,160</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">CASH AT BEGINNING OF PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,086</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,160</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">CASH AT END OF PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">94,276</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD>&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for:</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 10.35pt 0 0; text-align: center">The accompanying notes are
  an integral part of these financial statements.</P>
  
  
  <!-- Field: Page; Sequence: 6 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NULIFE SCIENCES, INC. AND SUBSIDIARIES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JUNE 30, 2017 and 2016</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - ORGANIZATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">NuLife Sciences
  Inc., formerly SmooFi, Inc. (the &quot;Company&quot;) was incorporated under the laws of the State of Nevada on October 15, 2013.
  The Company issued 7,250,000 shares of its common stock to our founder, Derek Cahill, as consideration for the purchase of a business
  plan along with a website.&nbsp;<FONT STYLE="background-color: white">On April 21, 2015, the Board of Directors of the Company
  approved a three-for-one forward stock split of the Company's common stock (the &ldquo;Forward Split&rdquo;). Accordingly, shareholders
  owning shares of the Company's common stock received two additional shares of the Company for each share they owned, and Mr. Cahill&rsquo;s
  7,250,000 shares became 21,750,000 shares. Prior to the Forward Split the Company had 10,128,600 shares issued and outstanding
  and following the Forward Split the Company has 31,085,800 shares issued and outstanding.&nbsp;</FONT>&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><I>Online marketplace
  and community</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company's
  initially-defined business strategy is to acquire and/or develop and market software and services that will significantly enhance
  the performance and functionality of the Internet services used by individuals and by small to medium sized businesses. The Company's
  products and services, essentially an online marketplace and community, will use proprietary technology that will enable users,
  both service requestors and service providers, to work collaboratively to obtain substantial improvements in performance, reliability
  and usability. Service requestors (people or companies requesting a service) name their own price, date and time for any service.
  A service requestor can also select qualifying criteria such as number of reviews or review rankings of a service provider. The
  first service provider who can provide that service, on that date, at that time and meets the service ranking requirements will
  get the project. The web site and the platform, originally titled www.AnytimeJobs.com experienced security issues shortly after
  it was launched and had to be taken down to correct the security problems. At the present time, the additional programming to eliminate
  the security problem has not been completed and the platform is not available online.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Once the security
  issues with the platform are resolved, the Company's online marketplace and online community will match up daily job or service
  requests and fill market demand for service requests throughout a particular local community, county or city and will connect local
  resources with local needs. A goal is to create jobs and provide market value for basic services by aggregating these low-cost
  services within each local market. This will maximize value for either the person or company requesting the service and for the
  person or company providing the service. In other words, service providers will get the best possible price for their service and
  the party requesting the service will pay the lowest possible price.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><I>Operations,
  Consulting and Advisory Services in the Organ Transplant segment of the Healthcare Industry</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2016,
  pursuant to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the assets of GandTex LLC,
  A Texas Limited Liability Company (&ldquo;GandTex&rdquo;), the Company formed 2 subsidiaries in the state of Nevada, NuLife BioMed,
  Inc., and NuLife Technologies, Inc. GandTex is a biomedical company focused on advancing human organ transplant technology and
  medical research. The assets being transferred consist of certain proprietary patents&nbsp;for&nbsp;eliminating the need for an
  organ or tissue match, and the necessity for anti-rejection drugs, as well as management of, and historical data for, animal trials
  conducted by GandTex.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 29, 2017,
  the Company announced the completion of an Asset Purchase Agreement to acquire all of the assets (the &ldquo;Asset Purchase&rdquo;)
  of GandTex was the owner of certain patents and licensed rights related to biomedical company focused on advancing human organ
  transplant technology and medical research. The assets consisted of certain proprietary patents for eliminating the need for an
  organ or tissue match, and the necessity for anti-rejection drugs, as well as management of, and historical data for, animal trials
  (the &ldquo;Animal Trials&rdquo;) conducted by a third party operating under the GandTex Assets (collectively, the &ldquo;GandTex
  Assets&rdquo;). Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the Company agreed to
  provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the GandTex Assets, the Company
  issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by a single individual
  Managing Member who beneficially owns 70% of GandTex. The Asset Purchase was approved by a majority of the Company&rsquo;s disinterested
  directors.</P>
  
  <!-- Field: Page; Sequence: 7 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 26, 2017,
  the Company&rsquo;s wholly owned subsidiary, NuLife Technologies Inc., formed and serves as the current Managing Member of NuLife
  Oncology Services LLC, a Wyoming limited liability company (&ldquo;NuLife Ocnology&rdquo;).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to
  have NuLife Oncology operate as a stand-alone joint venture between NuLife Technologies Inc. as a Co-Managing Member and one
  other recognized consulting organization in the healthcare patient, clinical &amp; genomic data collection, and <FONT STYLE="color: #2F2F2F">the
  pharmaceutical / diagnostic industries&nbsp;serve as a Co-Managing Member. AS of the date of this Report we do not have any
  agreements or letters of Intent signed with the prospective Co-Managing Member. </FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #2F2F2F">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; color: #2F2F2F">NuLife Oncology
  was created to address the Healthcare Professional Services Group focused on optimizing oncological data exchange for the pharmaceutical
  / diagnostic industries betterment of oncology patients, medical practices, and the pharmaceutical / diagnostic industries. It
  is our current intent to have NuLife Oncology focus on addressing the following Healthcare marketplace dynamics:</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt; color: #2F2F2F">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The capture and aggregation of large-scale patient clinical &amp;
  genomic data sets within oncology practices is quickly advancing, while plans to optimize the utility of such data remains poorly-defined.
  Intuitively, the oncology practices recognize the value of such data, but lack the sophistication to create monetization plans
  with the data.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1.5in; text-indent: -0.25in"><I>&nbsp;</I></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt; color: #2F2F2F">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The exchange of genomic data between healthcare providers and pharma/diagnostic
  companies is nearly non-existent; significant opportunities exist to facilitate efficient Patient &amp; Rx match both in pre-clinical
  and post-marketing settings. Through its network of oncology practices, NuLife <FONT STYLE="color: #2F2F2F">Oncology</FONT> will
  assimilate these data sources in order to &ldquo;repackage and sell&rdquo; to various oncology marketplace stakeholders.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>&nbsp;</I></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt; color: #2F2F2F">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There are no known corporate entities serving as data exchanges,
  which seek to benefit all contributors and consumers of these data. Data sale transactions are typically one-sided, whereas NuLife
  <FONT STYLE="color: #2F2F2F">Oncology</FONT> will serve as a &ldquo;revenue sharing&rdquo; partner with the oncology physician
  practices.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.15in; text-indent: -0.15in"><I>&nbsp;</I></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt; color: #2F2F2F">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The proliferation of Targeted Therapies and Molecular Diagnostic
  tests presents various challenges re: integrating new technologies within oncology practices. NuLife <FONT STYLE="color: #2F2F2F">Oncology</FONT>
  will partner with practices to ensure seamless integration of current and emerging new technologies by effectively sourcing, contracting
  and intermediating molecular testing on the practice&rsquo;s behalf. NuLife <FONT STYLE="color: #2F2F2F">Oncology</FONT> will accomplish
  this through a preferred and recommended network of diagnostic testing companies. Management of this process will serve as &ldquo;the
  gate&rdquo; through which NuLife <FONT STYLE="color: #2F2F2F">Oncology</FONT> secures access to genomic and clinical data from
  the practices. </FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">In short, NuLife Oncology aims to solve the data-exchange
  gap through:</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Democratization of appropriate low-cost diagnostic
  testing services</FONT></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integration of molecular data for improved patient
  outcomes</FONT></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokering data relationships between Pharma and
  oncology practices</FONT></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monetization of data with benefit to all Oncology
  Care stakeholders</FONT></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.75in; text-indent: 0.5in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Creating genomics-based research opportunities
  for oncology practices</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Basis of Presentation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company's
  financial statements are prepared using the accrual method of accounting. The Company has elected a September 30 fiscal year-end.
  These financial statements present the consolidated financial statements of NuLife Sciences, Inc. and its two wholly owned subsidiaries,
  NuLife Biomed, Inc. and NuLife Technologies, Inc., and NuLife Oncologies LLC, a newly formed Wyoming limited liability company
  for which NuLife Technologies Inc. currently serves as the Managing Member.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The unaudited
  interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission.
  The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are,
  in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information
  and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally
  accepted in the United States of America have been omitted pursuant to such rules and regulations. These condensed consolidated
  financial statements should be read in conjunction with the audited financial statements and notes for the year ended September
  30, 2016 included in our Annual Report on Form 10-K. The results of the nine-month periods ended June 30, 2017 are not necessarily
  indicative of the results to be expected for the full year ending September 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Cash Equivalents</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">For purposes of
  the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three months
  or less at the time of issuance to be cash equivalents. The Company does not have any cash equivalent as of June 30, 2017 and September
  30, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stock-based Compensation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company
  follows ASC 718-10,&nbsp;<I>Stock Compensation</I>, which addresses the accounting for transactions in which an entity
  exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains
  employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services
  received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited
  exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be
  recognized. The Company adopted a Non-Qualified Incentive Stock Compensation Plan pursuant to which the Company is reserving
  seven million (7,000,000) shares of Common Stock for issuance for services and the exercise of stock options. As of June 30
  ,2017 the Company has only issued one Stock Option for One Million Five Hundred Thousand (1,500,000) shares to its President,
  Fred G. Luke and has an agreement to issue One Million Five Hundred Thousand (1,500,000) shares to its CEO, John Hollister,
  but has not yet provided Mr. Hollister with the Option Agreement. Nonemployee share-based payments are measured at fair
  value, based on either the fair value of the equity instrument issued or on the fair value of the services received. We
  determine the fair value of common stock grants based on the price of the common stock on the measurement date (which is the
  earlier of the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, if
  there are sufficient disincentives to ensure performance, or the date at which the counterparty's performance is complete).
  We determine the fair value of preferred stock grants based on the price of the preferred stock as potentially converted into
  common stock and based on the underlying common stock on the measurement date (which is the earlier of the date at which
  a commitment for performance by the counterparty to earn the equity instruments is reached, if there are sufficient
  disincentives to ensure performance, or the date at which the counterparty's performance is complete).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of Estimates and Assumptions</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Preparation of
  the financial statements in conformity with accounting principles generally accepted in the United States requires management to
  make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from
  those estimates. The Company has adopted the provisions of ASC 260.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 9 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Loss per Share</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The basic loss
  per share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common
  shares during the year. The diluted loss per share is calculated by dividing the Company's net loss available to common shareholders
  by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
  is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share
  are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Fair Value Measurements and Disclosures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Fair value estimates
  discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2017
  and 2016. The respective carrying value of certain on-balance-sheet financial instruments, approximate their fair values. These
  financial instruments include cash, accounts receivable, accounts payable, accrued expenses and notes payable. Fair values were
  assumed to approximate carrying values for these financial instruments because they are short term in nature and their carrying
  amounts approximate fair values or they are receivable or payable on demand.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company uses
  fair value measurements under the three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure
  for fair value measures. The three levels are defined as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 4%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="width: 96%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&nbsp;inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&nbsp;inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&nbsp;inputs to the valuation methodology are unobservable and significant to the fair value.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD COLSPAN="3" STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="11" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair Value Measurements&nbsp;</B></FONT><BR>
  <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Using Fair Value Hierarchy</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD COLSPAN="3" STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 1</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 2</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 60%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes (net of discount) &ndash; June 30, 2017</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 10%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 10%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">217,173</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes (net of discount) &ndash; September 30, 2016</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,545</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability &ndash; June 30, 2017</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">283,800</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative liability &ndash; September 30, 2016</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169,221</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
  provides a summary of the changes in fair value of the Company&rsquo;s Promissory Notes, which are both Level 3 liabilities as
  of June 30, 2017:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2016</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">8,545</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif">Issuance of notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">763,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt discount on convertible notes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(78,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accretion of debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,727</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt discount on convertible notes due to beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(635,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accretion of debt discount due to beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">119,446</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance June 30, 2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">217,173</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company determined
  the value of its convertible notes using a market interest rate and the value of the derivative liability issued at the time of
  the transaction less the accretion. There is no active market for the debt and the value was based on the delayed payment terms
  in addition to other facts and circumstances at the end of June 30, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 10 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Derivative Financial Instruments</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company evaluates
  our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
  For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
  its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
  For stock-based financial instruments, the Company uses the Black-Scholes-Merton pricing model to value the derivative instruments.
  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity,
  is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current
  or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the
  balance sheet date.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The classification
  of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at
  the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value
  of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current
  or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet
  date.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company estimates
  the fair value of these instruments using the Black-Scholes option pricing model and the intrinsic value if the convertible notes
  are due on demand.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have determined
  that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price &ldquo;reset&rdquo;
  adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts
  in an Entity&rsquo;s Own Stock (&ldquo;ASC 815-40&rdquo;). Certain of the convertible debentures have a variable exercise price,
  thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares
  to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through
  earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as &ldquo;Other income
  (expense) - gain (loss) on change in derivative liabilities.&rdquo; Please refer to Note 8 below.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income Taxes</B></P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Income taxes are
  provided in accordance with ASC 740,&nbsp;<I>Income Taxes</I>. A deferred tax asset or liability is recorded for all temporary
  differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from
  the net change during the year of deferred tax assets and liabilities.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Deferred tax assets
  are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of
  the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax
  laws and rates on the date of enactment.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">No provision was
  made for Federal or State income taxes.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Advertising</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Advertising will
  be expensed in the period in which it is incurred. There have been no advertising expenses for the reporting periods presented.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intangible Assets</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Intangible assets
  with finite lives are amortized over their estimated useful life. The Company monitors conditions related to these assets to determine
  whether events and circumstances warrant a revision to the remaining amortization period. The Company tests its intangible assets
  with finite lives for potential impairment whenever management concludes events or changes in circumstances indicate that the carrying
  amount may not be recoverable. The original estimate of an asset's useful life and the impact of an event or circumstance on either
  an asset's useful life or carrying value involve significant judgment.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 11 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Reclassification</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In order to present
  comparable financial sheets, accrued expenses and due to related parties were reclassified as of September 30, 2016. This reclassification
  did not affect the amount of liabilities in total.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recently Issued Accounting Pronouncement</B>s</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In August 2014,
  the FASB issued ASU No. 2014-15, &quot;Presentation of Financial Statements &mdash; Going Concern (Subtopic 205-40), Disclosure
  of Uncertainties about an Entity's Ability to Continue as a Going Concern&quot;. Continuation of a reporting entity as a going
  concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent.
  Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently,
  there is no guidance under U.S. GAAP about management's responsibility to evaluate whether there is substantial doubt about an
  entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide
  that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments
  require management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles
  that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt,
  (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating
  effect of management's plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration
  of management's plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6)
  require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In February 2016,
  the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840).
  ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments
  in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early
  application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or
  entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently
  evaluating the impact of this new standard on its consolidated financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In March 2016,
  the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update (&quot;ASU&quot;) No. 2016-09, &ldquo;Compensation
  - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&rdquo; (&ldquo;ASU 2016-09&rdquo;). The
  standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax
  impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods
  within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the
  impact that the standard will have on its financial statements.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company reviewed
  all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC and
  they did not or are not believed by management to have a material impact on the Company's present or future financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 3 &ndash; GOING CONCERN</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The accompanying
  financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying
  financial statements, the Company had negative working capital of $651,221 and, having incurred net losses since inception, an
  accumulated deficit of $4,888,030 at June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">For the period
  ended June 30, 2017, management evaluated the Company's ability to continue as a going concern and concluded that substantial doubt
  has not been alleviated about the Company's ability to continue as a going concern. While the Company continues to explore further
  significant sources of financing, management's assessment was based on the uncertainty related to the amount and nature of such
  financing over the next twelve months.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The financial
  statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 12 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 &ndash; NOTES RECEIVABLE</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On January 15,
  2016, the Company entered into a secured promissory note in the amount of $46,400 to advance funds to the sellers of certain farm
  property in Colorado the Company was seeking to purchase. Closing was subject to financing and other contingencies per a non-binding
  Letter of Intent. This note had an interest rate of 8% per annum, with principal and unpaid and accrued interest originally due
  on June 30, 2016. On March 31, 2016, the Company entered into Amendment #1 to this note to (i) extend the due date to June 30,
  2016, unless the contemplated transaction closes prior thereto, in which case the note will be cancelled, (ii) reduce the principal
  to $31,400 to characterize $15,000 of the funds transferred to sellers as a non-refundable earnest money payment and (iii) stipulate
  that interest is to accrue on the lower $31,400 principal since inception. On June 30, 2016, the Company entered into Amendment
  #2 to this note to (i) extend the due date to September 30, 2016, unless the contemplated transaction closes prior thereto, in
  which case the note will be cancelled. On September 30, 2016, the Company determined this note to no longer be collectible. As
  such, the principal amount of $31,400, the non-refundable deposit amount of $15,000 and accrued interest in the amount of $2,228
  was written off and included in operating expense for the year ended September 30, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On August 17,
  2016, the Company entered into a secured promissory note in the amount of $25,000 to advance funds to the sellers of assets in
  regards to the Asset Purchase Agreement referenced in Note 1. This note has an interest rate of 8% per annum, with principal and
  unpaid and accrued interest due on February 17, 2017. On January 29, 2017, the note was deemed uncollectible, the principal amount
  of $25,000 and accrued interest in the amount of $904 was written off and included in operating expense for the nine months ended
  June 30, 2017. As of June 30, 2017, the total outstanding under this note including accrued interest is $-0-.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 5&nbsp;-
  INVESTMENT</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2016,
  pursuant to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the GandTex Assets the Company
  formed two subsidiaries in the state of Nevada, NuLife BioMed, Inc., and NuLife Technologies, Inc. GandTex is a biomedical company
  focused on advancing human organ transplant technology and medical research. The assets being transferred consist of certain proprietary
  patents&nbsp;for&nbsp;eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs, as well as
  management of, and historical data for, animal trials conducted by GandTex.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 29, 2017,
  the Company announced the completion of an Asset Purchase Agreement to acquire the assets (the &ldquo;Asset Purchase&rdquo;) of
  GandTex, LLC, a Texas limited liability company (&ldquo;GandTex&rdquo;). GandTex was the owner of certain patents and licensed
  rights related to biomedical company focused on advancing human organ transplant technology and medical research. The assets consisted
  of certain proprietary patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs,
  as well as management of, and historical data for, animal trials (the &ldquo;Animal Trials&rdquo;) conducted by a third-party operating
  using the GandTex Assets. Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the Company
  agreed to provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the Assets, the Company
  issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by a single individual
  Managing Member who beneficially owns 70% of GandTex. The Asset Purchase was approved by a majority of the Company&rsquo;s disinterested
  directors.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The fair
  value of the preferred stock amounted $2,500,000 is being treated as an expense instead of investment because it is deemed as Stock
  Based Compensation, not an Investment.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>NOTE&nbsp;6 - CONSULTING AGREEMENT</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On
  April 1, 2015, the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement,
  the Company will pay the consultant a monthly fee of $8,500 on the first day of each month with the payment deferred until the
  Company closes financing in the amount of $3 million or greater. Additionally, the Company was required to issue the consultant
  200,000 shares of common stock on October 1, 2015. During the nine months ended June 30, 2017 and 2016, the Company recorded stock
  based compensation expense in the amount of $-0- and $30,500 associated with the vesting of the common stock, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 13 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 28,
  2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.(&ldquo;Global&ldquo;), a Company owned
  by the Company&rsquo;s President Fred G. Luke (&ldquo;the &ldquo;Global Agreement&rdquo;), pursuant to which the Company retained
  Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve as the Company&rsquo;s
  President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing of the Company&rsquo;s
  its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received an aggregate of 55,000
  shares of restricted Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; NOTES PAYABLE</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, the Company had one note payable issued and outstanding to third party lenders with a total principle of $25,000 and accrued
  interest of $14,400. The note was due on June 30, 2015, has an interest rate of 12%. This note remains unpaid. The note is in default
  as of June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $10,611. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company (&ldquo;EWSD&rdquo;) of which Mr. Brian Loiselle,
  a former director of and consultant to the Company, was a managing member. On June 30, 2016, the Company entered into Amendment
  #1 to these three notes to extend the due date to the earlier of one week after the closing of a certain contemplated farm property
  acquisition or October 31, 2016. The three notes are currently in default. However, the default interest demand of 18% per month
  by Mr. Loiselle is being disputed by the Company due to the lack of provision for default interest in the notes. The three notes
  have been reclassified to non-related party debt. See also Note 11.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 8 &ndash; CONVERTIBLE NOTES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Convertible notes consist of the following:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 30, 2017</B></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2016</TD></TR>
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 63%; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due December 2017.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">50,025</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">50,025</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due August 2019.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due October 2019.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due November 2019.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible notes payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due December 2019.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">605,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt; padding-left: 10pt">Convertible note payable, annual interest rate of 12%, convertible into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common stock at a variable rate per share and due June 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unamortized debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(129,752</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(91,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount due to beneficial conversion feature</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(516,100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-)</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">217,173</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33,067</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-0-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible debt, net of current portion and debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">184,106</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2,
  2016, the Company amended and restated that certain outstanding promissory note of the Company, dated July 3, 2015, in the principal
  amount of $50,025. The replacement convertible promissory note matures on December 31, 2017 and bears interest at the rate of 8%
  per annum, and the principal and interest due thereunder may be prepaid at any time. The note, together with all interest as accrued,
  is convertible into shares of the Company&rsquo;s common stock at 50% of the trailing average highest closing bid price of the
  Company&rsquo;s common stock on the date of conversion. As of June 30, 2017, the note balance and accrued interest is $50,025 and
  $8,026, respectively.</P>
  
  <!-- Field: Page; Sequence: 14 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2016,
  the Company entered into those four (4) Note Purchase Agreements (collectively, the &ldquo;Purchase Agreements&rdquo;) in connection
  with the issuance of certain convertible promissory notes, dated August 1, 2016 (collectively, the &ldquo;Purchase Notes&rdquo;)
  in the aggregate principal amount of $50,000. All of the Purchase Notes are due in 36 months. The Purchase Notes bear interest
  at the rate of 8% compounded monthly. The Purchase Notes, together with all interest as accrued, is convertible into shares of
  the Company&rsquo;s common stock at 50% of the trailing average highest closing bid price of the Company&rsquo;s common stock on
  the date of conversion. Due to the beneficial conversion feature of these notes, the Company recorded $50,000 of debt discount
  as a contra liability and amortized $15,205 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the
  Purchase Notes balance and accrued interest is $50,000 and $3,649, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine
  months ended June 30, 2017, the Company entered into certain Note Purchase Agreements (collectively the &ldquo;Purchase Agreements&rdquo;)
  in connection with the issuance of certain convertible promissory notes, in the aggregate principal amount of $685,000. The Purchase
  Notes are due in 36 months. The Purchase Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together
  with all interest as accrued, are each convertible into shares of the Company&rsquo;s common stock at a conversion price of Eleven
  cents ($0.11) per share. Due to the beneficial conversion feature of these notes, the Company recorded $635,545 of debt discount
  as a contra liability and amortized $119,446 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the
  note balances and accrued interest are $685,000 and $31,506, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 26, 2017,
  the Company entered into a Securities Purchase Agreement (&ldquo;SAP&rdquo;) in connection with the issuance of a convertible promissory
  note (&ldquo;Note&rdquo;) in the aggregate principal amount of $78,000. The Note matures on June 30, 2018 (the &ldquo;Maturity
  Date&rdquo;), and bears interest at the rate of 12% per annum. After 180 days, the Note may not be prepaid. Any amount of principal
  or interest on this Note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from
  the due date. The Note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s common stock at
  a 35% discount to the lowest trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion
  Date. Due to the beneficial conversion feature of this note, the Company recorded $78,000 of debt discount as a contra liability
  and amortized $846 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the note balance and accrued
  interest is $78,000 and $103, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 9 &ndash; DERIVATIVE LIABILITY</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During August 2016,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $50,025. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s
  common stock at 50% of the trailing average highest closing bid price of the Company&rsquo;s common stock on the date of conversion.
  The Note accrues interest at a rate of 8% per annum and matures on December 31, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During August 2016,
  the Company entered into Loan Agreements with investors pursuant to which the Company issued convertible promissory notes in the
  principal amount of $50,000. The Notes are convertible into shares of common stock at an initial conversion price subject to adjustment
  as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s common
  stock at 50% of the trailing average highest closing bid price of the Company&rsquo;s common stock on the date of conversion. The
  Notes accrue interest at a rate of 10% per annum and mature on August 1, 2019.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During June 2017,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $78,000. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company&rsquo;s
  common stock at 65% of the trailing average highest closing bid price of the Company&rsquo;s common stock on the date of conversion.
  The Note accrues interest at a rate of 12% per annum and matures on June 30, 2018.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the variable
  conversion price associated with these convertible promissory notes, the Company has determined that the conversion feature is
  considered a derivative liability. The accounting treatment of derivative financial instruments requires that the Company record
  the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of
  each subsequent balance sheet date.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 15 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial fair
  value of the embedded debt derivative of $298,140 was allocated as a debt discount in the amount of $175,025 and excess $123,115
  was charged to interest expenses, loss on derivative. The fair value of the described embedded derivative was determined using
  the Black-Scholes Model with the following assumptions:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="width: 44%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 19%; line-height: 115%; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2017</FONT></TD>
      <TD STYLE="width: 19%; line-height: 115%; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2017</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%; text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD NOWRAP STYLE="width: 17%; line-height: 115%; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2016</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) dividend yield of</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) expected volatility of</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250%,</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311%,</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243% - 413%,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) risk-free interest rate of</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20% - 1.24%,</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47%,</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50% - 0.88%,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) expected life of</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-3 years</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) fair value of the Company&rsquo;s common stock of</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.67 per share.</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.60per share.</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.11 per share.</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine
  months ended June 30, 2017 and 2016, the Company recorded the loss in fair value of derivative and derivative expense in the amount
  of $39,579 and $-0-, respectively.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine months
  ended June 30, 2017, $39,727 and $-0-, were expensed in the statement of operation as amortization of debt discount related to
  above notes and shown as interest expenses, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table
  represents the Company&rsquo;s derivative liability activity for the period ended:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 83%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September 30, 2016</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 2%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 13%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169,221</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial measurement at issuance date of the notes</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103,520</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative expense</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative at period end</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,059</FONT></TD>
      <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance June 30, 2017</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">283,800</FONT></TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 &ndash; SHARE CAPITAL</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company is
  authorized to issue 475,000,000 shares of common stock and 25,000,000 shares of preferred stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 1, 2015,
  the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company granted
  200,000 shares of restricted common stock to the investor relations firm which fully vested on October 1, 2015. The final issuance
  resulted in 600,000 shares of restricted common stock due to the three-for-one forward stock split. On the date of the consulting
  agreement was entered into, April 1, 2015, the shares were valued at $1.00 per share which was the unadjusted share price prior
  to three-for-one forward stock split. The subject shares of common stock were issued on March 29, 2016. During the year ended September
  30, 2015, the Company recorded share based compensation expense in the amount of $200,000 associated with the vesting of the common
  stock granted. On March 31, 2016, the Company and the investor relations firm entered into Amendment #1 to the consulting agreement
  to suspend the monthly fee indefinitely until such time as the Company requests that the services resume.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On April 21, 2015,
  the Board of Directors of the Company approved a three-for-one forward stock split of the Company's common stock. Accordingly,
  shareholders owning shares of the Company's common stock will receive two additional shares of the Company for each share they
  own. The Company had 10,128,600 shares issued and outstanding prior to the forward stock split. At September 30, 2016 and September
  30,2015 the Company has 31,085,800 shares and 30,385,800 shares, respectively, of common stock issued and outstanding. The Company
  received notification from the Financial Industry Regulatory Authority (FINRA) on May 7, 2015, that it could proceed with the three-for-one
  forward stock split. Additional funds were reallocated from Additional Paid in Capital to the Common Stock account in an amount
  equal to the additional par value represented by the additional shares issued under the stock split. All share information presented
  in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the increased number of shares
  resulting from this transaction.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vested over a six-month period; accordingly, during the six months ended March 31, 2016, the Company recorded stock based compensation
  expense in the amount of $61,000 associated with vesting of the common stock granted. The subject shares of common stock were issued
  on March 29, 2016. During the year ended September 30, 2016, the Company recorded stock based compensation expense in the amount
  of $43,098, associated with vesting of common stock granted.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 31, 2016,
  the Company amended and restated its Articles of Incorporation. The purpose of the amendment and restatement of the Articles of
  Incorporation was to:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
      <TD STYLE="padding-left: 12.55pt; text-align: justify; line-height: 115%; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change the Company&rsquo;s name from &ldquo;SmooFi, Inc.&rdquo; to &ldquo;NuLife Sciences, Inc.&rdquo;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
      <TD STYLE="padding-left: 12.55pt; text-align: justify; line-height: 115%; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symbol change from &ldquo;SMFI&rdquo; to &ldquo;NULF&rdquo;;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
      <TD STYLE="padding-left: 12.55pt; text-align: justify; line-height: 115%; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase the number of authorized shares of Preferred Stock to 25,000,000;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
      <TD STYLE="padding-left: 12.55pt; text-align: justify; line-height: 115%; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase the number of authorized shares of Common Stock to 475,000,000;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
      <TD STYLE="width: 96%; padding-left: 12.55pt; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Define, with respect to the Preferred Stock, the manner in which the Board may define the powers, preferences, rights, and restrictions thereof. &nbsp;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Concurrent with
  the Company&rsquo;s increase of its authorized common and preferred stock, the Company requested and received from, the Financial
  Industry Regulatory Authority, approval for a name change from Smoofi, Inc. to NuLife Sciences, Inc., and a symbol change from
  &ldquo;SMFI&rdquo; to &ldquo;NULF&rdquo;.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also on October
  31, 2016, the Company adopted a 2016 Non-Qualified Incentive Stock Compensation Plan (the &ldquo;Compensation Plan&rdquo;), and
  reserved 7,000,000 shares for issuance from the Compensation Plan. As of the date of this report no shares have been issued from
  the Compensation Plan.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2016,
  the Company amended and restated its Bylaws, providing for a change in the Company&rsquo;s name from &ldquo;SmooFi, Inc.&rdquo;
  to &ldquo;NuLife Science, Inc.&rdquo;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2016,
  the Board approved the Certificates of Designation to create and provide for the rights, preferences, and privileges of 2,000,000
  shares of the Company&rsquo;s Series A Convertible Preferred Stock and 10,000,000 shares of the Company&rsquo;s Series B Convertible
  Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Description of Preferred Stock:</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Series A Preferred
  Stock</U></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As authorized in the Company&rsquo;s Amended and Restated Articles
  of Incorporation, the Company has 2,000,000 shares of Series A Preferred Stock authorized with the following characteristics:</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holders of the Series A Stock shall be entitled to receive dividends
  or other distributions with the holders of the Common Stock on an &ldquo;as converted&rdquo; basis when, as, and if declared by
  the Directors of the<FONT STYLE="font-family: PMingLiU,serif">&#12288;</FONT>Corporation.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holders of shares of Series A Preferred Stock, upon Board of Directors approval, may convert
  at any time following the issuance upon sixty-one (61) day written notice to the Corporation. Each share of Series A Preferred
  Stock shall be convertible into such number of fully paid and non-assessable shares of Common Stock as is determined by multiplying
  the number of issued and outstanding shares of the Corporation&rsquo;s Common Stock together with all other derivative securities,
  including securities convertible into or<FONT STYLE="font-family: PMingLiU,serif">&#12288;</FONT>exchangeable for Common Stock,
  whether or not then convertible or exchangeable (b) subscriptions, rights, options and warrants to purchase shares of Common Stock,
  whether or not then exercisable, but entitled to vote on matters submitted to the Shareholders </FONT></TD></TR>
  </TABLE>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in"></P>
  
  
  <!-- Field: Page; Sequence: 17 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">(collectively, &ldquo;Derivative
  Securities&rdquo;), issued by the Corporation and outstanding as of the Date of Conversion, by .000001, then multiplying that number
  of shares of Series A Stock to be converted.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In case of any consolidation or merger of the Corporation, the Corporation
  shall mail to each holder of Series A Stock at least thirty (30) days prior to<FONT STYLE="font-family: PMingLiU,serif">&#12288;</FONT>the
  consummation of such event, a notice thereof and each such holder shall have the option to either (i) convert such holder&rsquo;s
  shares of Series A Shares into shares of Common Stock pursuant to this paragraph and thereafter receive the number of shares of
  Common Stock or other securities or property, or cash, as the case may be, to which a holder of the number of shares of Common
  Stock of the Corporation deliverable upon conversion of such Series A Stock would have been entitled upon conversion immediately
  preceding such consolidation, merger or conveyance, or (ii) exercise such holder&rsquo;s rights pursuant to Section 8.1(a) hereof;
  provided however that the Series A Stock shall not be subject to or affected as to the number of Conversion Shares or the redemption
  or liquidation price by reason of any reverse stock split affected prior or as a result of any reorganization.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In the event of a liquidation, the holders of shares of the Series
  A Stock shall be entitled to receive, prior to the holders of the other series of Preferred Stock and prior and in preference to
  any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the Corporation
  by reason of their ownership of such stock, an amount equal to Five Dollar ($5.00) per share with respect to each share of Series
  B Stock owned as of the date of Liquidation, plus all declared but unpaid dividends with respect to such shares, and thereafter
  they shall share in the net Liquidation proceeds on an &ldquo;as converted basis&rdquo; on the same basis as the holders of the
  Common Stock.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The holders of each share of Series A Stock shall have that number
  of votes as determined by multiplying the number of issued and outstanding shares of the Corporation&rsquo;s Common Stock together
  with all other derivative securities issued by the Corporation and outstanding as of the Date of Conversion, whether or not then
  convertible or exchangeable, entitled to vote on matters submitted to the Shareholders, by .000001, then multiplying that number
  of shares of Series A Stock to be converted.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Corporation shall have the option to redeem all of the outstanding
  shares of Series A Stock at any time on an &ldquo;all or nothing&rdquo; basis, unless otherwise mutually agreed in writing between
  the Corporation and the holders of shares of Series A Stock holding at least 51% of such A Stock, beginning ten (10) business days
  following notice by the Corporation, at a redemption price the higher of (a)Five Dollar ($5.00) per share, or (b) Fifty percent
  (50%) of the trailing average highest closing Bid price of the Corporation&rsquo;s Common Stock as published at www.OTCMarkets.com
  or the Corporation&rsquo;s primary listing exchange on the date of Notice of redemption, unless otherwise modified by mutual written
  consent between the Corporation and the Holders of the Series A Stock (the &quot;Conversion Price&quot;). Redemption payments shall
  only be made in cash within sixty (60) days of notice by the Corporation to redeem.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The shares of Series A Stock acquired by the Corporation by reason of conversion or otherwise
  can be reissued, but only as an amended class, not as shares of Series A Stock.</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt"></FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Series B Preferred
  Stock</U></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In conjunction with the Asset Acquisition
  with GandTex, as authorized in the Company&rsquo;s Amended and Restated Articles of Incorporation, the Company initially filed
  a Certificate of Designation creating a series A Preferred Stock consisting of 10,000,000 shares of Series B Preferred Stock with
  the following characteristics:</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
  </FONT><FONT STYLE="font-size: 10pt">Holders of shares of Series B Preferred Stock, upon Board of Directors approval, may convert
  at any time following the issuance upon sixty-one (61) day written notice to the Corporation. Each share of Series B Preferred
  Stock shall be convertible into such number of fully paid and non-assessable shares of Common Stock as is determined by </FONT></P>
  
  
  <!-- Field: Page; Sequence: 18 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">percentage of the net income which
  is achieved by SMFI and its subsidiaries (the &ldquo;Actual Net Income &ldquo;) versus the projections (detailed in Exhibit A to
  this Certificate of Designation of Series B Convertible Preferred) provided by GandTex (the &ldquo;Projected Net Income&rdquo;)
  at any time during the two (2) year term following the Closing of the Purchase Agreement. This calculation will be made by dividing
  the Actual Net Income achieved by SMFI and its subsidiaries related to the development and commercialization of the GandTex Assets
  by the Projected Net Income (attached hereto as Exhibit A to this Certificate of Designation of the Series B Convertible Preferred
  Stock) on the Notice to Convert (as defined below), then dividing that product into 1 share of Series B Stock. The formula of this
  calculation is:</P>
  
  <P STYLE="font: 10pt/normal Arial Unicode MS,sans-serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom; width: 66%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Share of Series B Stock</FONT></TD>
      <TD STYLE="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</FONT></TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">= of Common</P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Upon Conversion of</P></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>(Actual Net Income)</U></FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Share of Series B</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Projected Net Income)</FONT></TD>
      <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holders of the Series B Stock shall be entitled to receive dividends
  or other distributions with the holders of the Common Stock on an &ldquo;as converted&rdquo; basis when, as, and if declared by
  the Directors of the Corporation.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In case of any consolidation or merger of the Corporation, the Corporation
  shall mail to each holder of Series B Stock at least thirty (30) days prior to the consummation of such event, a notice thereof
  and each such holder shall have the option to either (i) convert such holder&rsquo;s shares of Series B Shares into shares of Common
  Stock pursuant to this Paragraph 3 and thereafter receive the number of shares of Common Stock or other securities or property,
  or cash, as the case may be, to which a holder of the number of shares of Common Stock of the Corporation deliverable upon conversion
  of such Series B Stock would have been entitled upon conversion immediately preceding such consolidation, merger or conveyance,
  or (ii) exercise such holder&rsquo;s rights pursuant to Section 9.1(a) hereof.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In the event of a liquidation, the holders of shares of the Series
  B Stock shall be entitled to receive, second to the holders of Series A Preferred Stock, but prior to the holders of the other
  series of Preferred Stock and prior and in preference to any distribution of the assets or surplus funds of the Corporation to
  the holders of any other shares of stock of the Corporation by reason of their ownership of such stock, an amount equal to One
  Dollar ($1.00) per share with respect to each share of Series B Stock owned as of the date of Liquidation, plus all declared but
  unpaid dividends with respect to such shares, and thereafter they shall share in the net Liquidation proceeds on an &ldquo;as converted
  basis&rdquo; on the same basis with the holders of the Common Stock.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Shares of Series B Preferred Stock shall have no voting rights in
  respect of matters submitted for a vote of the holders of Common Stock;</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Corporation shall have the option to redeem all of the outstanding
  shares of Series B Stock at any time on an &ldquo;all or nothing&rdquo; basis, unless otherwise mutually agreed in writing between
  the Corporation and the holders of shares of Series B Stock holding at least 51% of such A Stock, beginning ten (10) business days
  following notice by the Corporation, at a redemption price of One Dollar ($1.00) per share. Redemption payments shall only be made
  in cash within sixty (60) days of notice by the Corporation to redeem.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The shares of Series B Stock acquired by the Corporation
                                                                                                                                                    by
                                                                                                                                                    reason of conversion or otherwise can be reissued, but only as an amended class, not as shares of Series B Stock.</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in"></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.25in"></P>
  
  
  <!-- Field: Page; Sequence: 19 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">As
  described in Footnote 5 above, pursuant to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board
  approved the issuance of 10,000,000 shares of the Company&rsquo;s Series B Convertible Preferred Stock to GandTex. The shares were
  released to GandTex concurrent with the closing on January 29, 2017. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the &ldquo;Conversion Agreement&rdquo;) in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC(&ldquo;MZ&rdquo;) by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the &ldquo;Released Debt&rdquo;) together with a release by MZ in favor
  of the Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of
  fees or costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the
  Conversion Agreement, and in exchange for the release, the Company issued to MZ an aggregate of 55,000 shares of restricted Series
  A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Valuation of Series A and Series
  B Preferred Stock.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
  initial Certificate of <B>Desig</B>nation for both the Series A Stock and the Series B Stock had very similar characteristics and
  the same requirement that any conversion must be approved by the Company&rsquo;s Board of Directors limits the ability of the holders
  to convert both the Series A Stock and the Series B Stock. In part, each of the two Certificates of Designation initially had the
  following requirements,&rdquo;<I>3.1 <U>Conversion.&nbsp;</U>Upon Board of Directors approval, each share of Series A [B] Preferred
  Stock shall be convertible, subject to notice requirements of paragraph 3.2, at any time following the issuance of such shares
  Series A [B] Stock, into such number of fully paid and non-assessable shares of Common Stock&hellip;&rdquo;.</I> This limiting
  ability to convert the Series A [B] Stock significantly reduces their Fair Market Value. However, by utilizing the most readily
  available information and analogy, in the case of both the Series A Stock and Series B</FONT><FONT STYLE="font-family: PMingLiU,serif">&#12288;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
  this would be the issuance of the Series A Stock to MZHCI, a non-affiliate, for the extinguishment of debt of $13,750 for 55,000
  shares of Series A Stock, or $.25/share. By analogy, the 55.000 shares of Series A stock issued to Global Business Strategies Inc.
  (&ldquo;GBSI&rdquo;) were also valued at $.25 per share: The Series B Stock issued to GandTex, again by analogy, was also valued
  at $.25 per share.</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Utilizing this model,
  the Series A shares issued to MZHCI and GBSI were valued in the aggregate at $13,750 each, and the Series B shares issued to GandTex
  were initially valued at $2,500,000 and its being treated as an expense.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, as a result
  of the delayed onset of revenue and the regulatory approval timelines, the original estimates as to the timelines for the Animal
  Trials, making it impact able for the Company to proceed, or to achieve the projected benchmarks as to the completion date of the
  Animal Trials and obtaining approval from the requisite regulatory bodies as originally represented at Closing. As a result, the
  Company agreed to amend certain aspects of the GandTex Asset Acquisition Agreement, including the conversion formula of the Series
  B Convertible Preferred Stock issued to GandTex. The Amended and Restated Certificate of Designation creating a Series B Preferred
  Stock is to be amended to change the terms of conversion, and eliminated the requirement that GandTex, or any assignee of any of
  the Series B Stock, obtain approval that any conversion must be approved by the Company&rsquo;s Board of Directors, with all other
  of the original terms remaining unchanged. The Amended and Restated Certificate of Designation for the Series B Stock has not yet
  been filed with the state of Nevada, but will be shortly after we receive fully the executed Amendment Documents -see NOTE 13&nbsp;-
  SUBSEQUENT EVENTS. Pursuant to the proposed amended conversion features, the 10,000,000 shares of Series B Preferred Stock can
  be converted as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-indent: 0.25in; background-color: white; color: #010102"><B>&ldquo;3.0&#9;Conversion
  into Common Stock. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 16.05pt 0.05pt 0 18.2pt; text-align: justify; text-indent: 31.3pt; background-color: white"><FONT STYLE="color: #010102">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion.</U>
  One million shares of Series B Prefer</FONT><FONT STYLE="color: #222222">r</FONT><FONT STYLE="color: #010102">ed Stock shall be
  convertible into two million shares (l-for-2 ratio) of common stock of the Co</FONT><FONT STYLE="color: #222222">r</FONT><FONT STYLE="color: #010102">poration</FONT><FONT STYLE="color: #222222">,
  </FONT><FONT STYLE="color: #010102">subject to notice requ</FONT><FONT STYLE="color: #222222">i</FONT><FONT STYLE="color: #010102">rements
  of pa</FONT><FONT STYLE="color: #222222">r</FONT><FONT STYLE="color: #010102">agraph 3.2</FONT><FONT STYLE="color: #393B39">, </FONT><FONT STYLE="color: #010102">one
  year from the date the holder receives its shares of Series B Preferred Stock</FONT><FONT STYLE="color: #222222">, </FONT><FONT STYLE="color: #010102">into
  such number of fully paid and non-assessable shares o</FONT><FONT STYLE="color: #222222">f </FONT><FONT STYLE="color: #010102">Common
  Stock. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 17.5pt 0.8pt 0 0.25in; text-align: justify; text-indent: 33.1pt; background-color: white"><FONT STYLE="color: #010102">N</FONT><FONT STYLE="color: #222222">i</FONT><FONT STYLE="color: #010102">ne
  million shares of Series B P</FONT><FONT STYLE="color: #222222">r</FONT><FONT STYLE="color: #010102">eferred Stock shall be convertible
  into twenty-seven million shares (l-for-3 ratio) of Common Stock</FONT><FONT STYLE="color: #222222">, </FONT><FONT STYLE="color: #010102">subject
  to notice requirements of paragraph 3.2</FONT><FONT STYLE="color: #222222">, </FONT><FONT STYLE="color: #010102">at </FONT><FONT STYLE="color: #222222">s</FONT><FONT STYLE="color: #010102">uch
  time onl</FONT><FONT STYLE="color: #222222">y </FONT><FONT STYLE="color: #010102">when the Corporation has annual gross revenues
  of $60</FONT><FONT STYLE="color: #222222">,</FONT><FONT STYLE="color: #010102">000,000 deriv</FONT><FONT STYLE="color: #222222">i</FONT><FONT STYLE="color: #010102">ng
  from the Gandy</FONT><FONT STYLE="color: #222222">/</FONT><FONT STYLE="color: #010102">Gandtex patents or processes, into </FONT><FONT STYLE="color: #222222">s</FONT><FONT STYLE="color: #010102">uch
  number of fully paid and non-assessable shares of Common Stock.&rdquo; </FONT></P>
  
  <!-- Field: Page; Sequence: 20 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 17.5pt 0.8pt 0 0.25in; text-align: justify; background-color: white"><FONT STYLE="color: #010102"></FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Stock Options</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the
  Employment Agreement with Mr. Hollister, Mr. Hollister is to be granted option to purchase up to 1,500,000 shares of the Company&rsquo;s
  Common Stock. However, as of the date of this report the option price of the underlying shares has not been calculated, and the
  Option Agreement has not been executed &ndash; see Footnote 13. Subsequent Events.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company&rsquo;s President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement (the &ldquo;Option Agreement&rdquo;) which was Fourteen cents ($0.14)
  per share and subject to certain adjustments on November 15, 2016. The options vested immediately.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Stock option transactions for the
  nine months ended June 30, 2017 are summarized as follows:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted Average</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted Average Remaining</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Term</B></P></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid">
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P>
          <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Intrinsic Value</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 43%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, September 30, 2016</B></FONT></TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 24%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.14</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">186,904&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding, June 30, 2017</B></FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.14</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2017</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.0.14</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD>
      <TD NOWRAP STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial fair
  value of the option was $186,904 charged to operating expense during the nine months ended June 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; border-collapse: collapse">
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; width: 59%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) dividend yield of</FONT></TD>
      <TD STYLE="vertical-align: top; width: 14%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 26%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%;</FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) expected volatility of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236%,</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) risk-free interest rate of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28%,</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) expected life of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years, and</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) fair value of the Company&rsquo;s common stock of</FONT></TD>
      <TD STYLE="vertical-align: top; line-height: 115%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.13 per share.</FONT></TD>
      <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair value
  of options exercised in the three and nine months ended June 30, 2017 and 2016 was $0 and $0, and $0 and $0, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
  recorded $0 and $43,098, and $2,700,654 and $43,098 of stock compensation expense in the statements of operations for the three
  and nine months ended June 30, 2017 and 2016, respectively, related to non-vested share-based compensation arrangements granted
  under existing stock option plans.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As of June
  30, 2017, there was $0 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted
  under existing stock option plans.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 11 - RELATED PARTY TRANSACTIONS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="background-color: white">In
  April of 2015 Mr. Brian Loiselle, a former director of the Company, agreed to transfer his ownership interest in a cannabis farm
  and related equipment known as the &quot;Tamarack Project&quot;, which was the subject of a certain Letter of Intent to which the
  Company was a party. In addition, it was proposed that Mr. Cahill sell all of his 21,750,000 shares of the Company to Blue River
  Equity LLC, an Arizona Limited Liability Company (&ldquo;Blue River&rdquo;), a company controlled by Mr. Loiselle. The transfer
  of the Tamarack Project, and other projects which Mr. Loiselle offered in substitution for the Tamarack Project were never acquired
  by Mr. Loiselle and, therefore could not be transferred to the Company, resulting in a breach of the representations by Mr. Loiselle,
  for himself and on behalf of Blue River, and the failure of Mr. Loiselle and/or Blue River to cause any property to be transferred
  into </FONT></P>
  
  
  <!-- Field: Page; Sequence: 21 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">the
  Company. Consequently, as a result of the breach and failure to deliver the primary consideration for the shares held by Mr. Cahill.
  Mr. Cahill never transferred the subject shares thereby voiding the agreement between himself and Blue River, and retained Beneficial
  Ownership of the subject shares as evidenced by Mr. Cahills filing of a Beneficial Ownership Report on Form SC-13G on October 4,
  2016.</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="background-color: white">In
  addition, Mr. Loiselle induced the Company to make a non-refundable payment of $50,000 in connection with his attempt to purchase
  a replacement cannabis farm and property, the &ldquo;Stroud Farm&rdquo;, which never closed and the $50,000 was written off in
  the year ended September 30, 2015. After giving Mr. Loiselle several extensions of time to perform on his proposed multi-part transaction,
  we severed relations with Mr. Loiselle in August 2016. As of September 30, 2016, $53,200 was due to Mr. Loiselle and included as
  Due to Related Party which is in dispute as described below.</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Effective January
  1, 2016, in recognition of the absence of employment and consulting agreements and the time commitment to the Company on the part
  Mr. Sean Clarke, the Company's Chief Financial Officer and sole director, and Brian Loiselle, a former member of the Board of Directors,
  respectively, the Board of Directors on March 31, 2016 approved monthly compensation in the amount of $10,000 to be paid to Mr.
  Sean Clarke and Brian Loiselle, to be deferred and accrued and only paid following the Closing of the purchase of the Stroud Farm
  and at such time as the Company has the necessary financial resources. Effective April 1, 2016, such monthly compensation was revised
  from $10,000 to $5,000, but the Board of Directors reaffirmed that such payment was to be deferred and accrued, and only paid following
  the Closing of the purchase of the Stroud Farm and at such time as the Company has the necessary financial resources At September
  30, 2016, $53,200 has been accrued and is included in accrued expenses<B>.&nbsp;</B>However, the Company severed the relationship
  with Mr. Loiselle in August 2016 following the failure of close on the purchase the Stroud Farm and, therefore, the Company is
  disputing the obligation for payment of these accrued consulting fees.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">As
  of June 30, 2017, the Company had three notes payable issued and outstanding with an entity controlled by Mr. Loiselle with a
  total principle of $74,500 and accrued interest of $10,611. The three notes, in the amount of $47,000, $15,000 and $12,500,
  were issued on January 14, 2016. February 10, 2016 and February 29, 2016, respectively. The three notes are due on the
  earlier of one week after the closing of a certain contemplated farm property acquisition or July 31, 2016, and have an
  interest rate of 10%. The related party for all three notes is EastWest Secured Developments, LLC; an Arizona Limited
  Liability Company (&ldquo;EWSD&rdquo;) of which Mr. Brian Loiselle, a director of and consultant to the Company, is a
  managing member. On June 30, 2016, the Company entered into Amendment #1 to these three notes to extend the due date of the
  three notes is October 31, 2016. As of March 31, 2017, the Company owed EWSD $53,200 of accrued and unpaid services which is
  reported as accrued expenses. Mr. Loiselle&rsquo;s services terminated in July 2016 ending his affiliation with the Company
  and therefore neither he nor EWSD were considered a Related Party at June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">On
  April 22, 2015, the Company and&nbsp;Newport Board Group entered into an&nbsp;Advisory Services Agreement whereby Mr. Donahue would
  serve as the Company's Chief Operating Officer. The term of the initial agreement was for 60 days. The Board of Directors approved
  by resolution to extend the Agreement with the Newport Board Group on June 9, 2015, but no definitive agreement was signed and
  no set termination date was set; however, the resolutions provided for either party to terminate the extension at any time with
  30 days' written notice. The monthly fee under the original agreement was $4,000 to be paid monthly for Mr. Donahue to serve as
  the Chief Operations Officer and was negotiated and connected to the original proposed transfer of the Tamarack Project to the
  Company by Mr. Loiselle.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">During
  the nine months ended June 30, 2017, the Company paid $-0- to Newport Board Group, with an additional $59,633 of monthly fees deferred
  and included as accrued expenses at June 30, 2017. During the nine months ended June 30, 2016, the Company paid $-0- to Newport
  Board Group, with an additional $21,500 of monthly fees deferred and included as Due to Related Party at September 30, 2016. The
  Company terminated the extension in September 2016, effective October 15, 2016. The Company has continued to defer and accrue all
  additional fees through October 15, 2016. On August 7, 2015, the Company granted 100,000 shares of restricted common stock to Mr.
  John Donahue, the Company&rsquo;s former Chief Operations Officer. As of June 30, 2017, the Company owed Newport Board Group $59,633
  of accrued and unpaid services which is reported as accrued expenses, but Mr. Donahue&rsquo;s services terminated in September
  2016 ending his affiliation with the Company and therefore was not considered a Related Party at June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">As
  of June 30, 2017, the Company owed Mr. Clarke and Mr. Luke $52,500 and $-0-, respectively, of accrued and unpaid compensation.
  These amounts are included as Due to Related Party at June 30, 2017.</P>
  
  
  <!-- Field: Page; Sequence: 22 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 16
  2016 we asked Mr. John Hollister to join our management team as our Chief Executive Officer. Due to the financial constraints of
  the Company Mr. Hollister did not accept the offer. However, in October 2016 Mr. Hollister agreed to serve as a consultant, then
  as our interim our Chief Executive Officer, pending the completion of the sale the Purchase Notes. A definitive agreement was agreed
  upon and executed between the Company and Mr. Hollister on May 15, 2017, and contained the agreement for the Company to grant Mr.
  Hollister Options to purchase up to 1,500,000 shares of the Company&rsquo;s Common Stock, vesting upon certain events. The Option
  Agreement has not yet been executed. A copy of the Employment Agreement with Mr. Hollister was filed on Form 8-K on May 17, 2017-</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company&rsquo;s President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement (the &ldquo;Option Agreement&rdquo;) which was Fourteen cents ($0.14)
  per share and subject to certain adjustments on November 15, 2016.&nbsp;The options are valued at $186,904 and recorded as expense
  during the nine months ended June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 15,2017 the
  Company entered into an Employment Agreement with Mr. John Hollister to serve as the CEO of the Company. In addition to his role
  as CEO, Mr. Hollister will serve as the President of NuLife BioMed and be in charge of all aspects of the Animal Trials, review
  of the data submitted to the Food and Drug Association (&ldquo;FDA&rdquo;), and the Clinical Trials, subject to the approval by
  the FDA of our Animal Trial results and conclusions.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  March, 2017, we retained Dr. Youxue Wang MD, PhD to serve as the Director of Research for NuLife Biomed Inc. Doctor Wang has been
  working for several months for us in the development of the pre-clinical pig study protocol, which was recently up-loaded to the
  review board at Florida International University (&ldquo;FIU&rdquo;) for approval. We currently finalized the terms of an Advisory
  Agreement with South Broward Hospital District d/b/a Memorial Healthcare System</FONT> (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorial&rdquo;),
  the current employer of Doctors Arenas and Hranjec, both transplant surgeons, to perform the actual organ removal and replacement
  during the Animal Trials. Doctors Wang, Arenas, and Hranjec have recently received medical clearance from FIU to conduct the surgeries.&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 12&nbsp;&ndash;
  LEASE AGREEMENT</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During May 2017,
  the executed a 5-year lease for a laboratory at NOVA Southeastern University at which the Company will be utilizing the NuLife
  Technique to process organs, as well as conducting bench research to better characterize and assess the impact of the technique.
  The lease calls for monthly payments of $2,582, which includes the initial base rent of $1,925 along with applicable taxes and
  shared operating expenses. The lease required a security deposit in the amount of $4,871 and requires a 4% increase in base rent
  annually. Rent expense for the nine months ended June 30, 2017 and 2016 was $2,742 and $-0-, respectively.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future minimum lease
  payments are as follows for the years ending:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 11pt Calibri, Helvetica, Sans-Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2017 (remaining three months)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,775</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,408</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,344</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,318</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,331</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,016</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">123,192</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 13&nbsp;-
  CONTINGENCY</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
  of June 30, 2017, as described in Note 11, the Company has accrued $53,200 in Due to Related party - Mr. Loiselle</FONT>,&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">note
  payable of $74,500&nbsp;and accrued interest of $10,611 due EWSD. At June 30,2017 the Company owed EWSD the aggregated amount of
  $138,311, which is past due and has been in default since October 31, 2016. On top of the amount accrued by the Company, Mr. Loiselle
  had demanded for a penalty fee of $101,235, which is approximately 18% monthly default rate on the amount past due. We believe
  the penalty fee imposed is invalid and are currently in dispute with Mr. Loiselle.</FONT></P>
  
  <!-- Field: Page; Sequence: 23 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>NOTE 14
  - SUBSEQUENT EVENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aa
  result of third-party delays related to the Company (a) gaining approval for its &ldquo;Protocal&rdquo; for the Animal Trials,
  (b) finalizing the terms of the Lease for its Lab facilities at NOVA Southeastern University, (c) finalizing the terms of the agreement
  with South Broward Hospital District d/b/a Memorial Healthcare System</FONT> (&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorial&rdquo;),
  the current employer of the two transplant surgeons who the Company intends to retain to carry out the remaining Animal Trials,
  and (d) other issues out of the control of the Company, the original estimates as to the timelines for the Animal Trials, revenue
  projections , and other representations by GandTex in the original GandTex Asset Acquisition Agreement, made it impact able for
  the Company to rely on the original projected benchmarks as to the completion date of the Animal Trials, obtaining approval from
  the requisite regulatory bodies, or the revenue projections as originally represented by GandTex at Closing. As a result, GandTex
  agreed to amend certain aspects of the Asset Acquisition Agreement, and agreed to provide us with a Lockup Agreement and an Indemnity
  Agreement. In consideration for these added agreements (the &ldquo;Amendment Documents&rdquo;), we agreed to amend the conversion
  formula of the Series B Convertible Preferred Stock issued to GandTex and take the GandTex Assets subject to a Royalty Agreement.
  The Amendment Documents will be included as Exhibits in an Form 8-K filed by the Company concurrently with the countersignature
  of the documents and the filing of the Amended and Restated Certificate of Designation of the Series B Convertible Preferred Stock.
  </FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We finally resolved
  the majority of the causes of delays and resumed Animal Trials during the first week in August 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 24 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_003"></A>ITEM 2. MANAGEMENT'S DISCUSSION AND
  ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The information contained in this
  Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended September 30, 2016
  and presumes that readers have access to, and will have read, the &quot;Management's Discussion and Analysis of Financial Condition
  and Results of Operations&quot; and other information contained in such Form 10-K. The following discussion and analysis also should
  be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Except for historical information,
  the matters discussed in this section are forward looking statements that involve risks and uncertainties and are based upon judgments
  concerning various factors that are beyond the Company's control. Consequently, and because forward-looking statements are inherently
  subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed
  in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report.
  We strongly encourage investors to carefully read the factors described elsewhere in this report in the section entitled &quot;Risk
  Factors&quot; for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking
  statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q.
  The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere
  in this report.</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Company Overview</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">As
  a result of the Company not receiving the working capital promised by certain third parties, development of the two business segments
  described below has been slow, and generated less than expected revenue since its inception on October 15, 2013. However, in August
  2016 we elected to modify our initial business plan to suspend pursuing our online marketing business and the subsequent cannabis
  activities in favor of the acquisition and development of the patents and other rights owned by </FONT>GandTex<FONT STYLE="background-color: white">.
  As part of this new direction into the medical and healthcare industry, subsequent to the date of this report &ndash; See Subsequent
  Events &ndash; we acquired the GandTex License and Patent rights related to a proprietary technique for organ transplants, as discussed
  below.</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Online marketplace
  and community</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">The
  Company's initially-defined business strategy is to acquire and/or develop and market software and services that will significantly
  enhance the performance and functionality of the Internet services used by individuals and by small to medium sized businesses.
  The Company's products and services, essentially an online marketplace and community, will use proprietary technology that will
  enable users, both service requestors and service providers, to work collaboratively to obtain substantial improvements in performance,
  reliability and usability. Service requestors (people or companies requesting a service) name their own price, date and time for
  any service. A service requestor can also select qualifying criteria such as number of reviews or review rankings of a service
  provider. The first service provider who can provide that service, on that date, at that time and meets the service ranking requirements
  will get the project</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt; background-color: white">The
  Company's online marketplace and online community was designed to match up daily job or service requests and fill market demand
  for service requests throughout a particular local community, county or city and will connect local resources with local needs.
  A goal is to create jobs and provide market value for basic services by aggregating these low-cost services within each local market.
  This will maximize value for either the person or company requesting the service and for the person or company providing the service.
  In other words, service providers will get the best possible price for their service and the party requesting the service will
  pay the lowest possible price. Since the acquisition of the organ transplant technology, we have narrowed the focus of our platform
  to the healthcare industry and intend to include a section in our platform dedicated to providing educational information as to
  the various options available to those in need of transplants.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 25 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Operations,
  Consulting and Advisory Services in the Organ Transplant segment of the Healthcare Industry</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">With
  the acquisition of the GandTex technology the Company intends to move into the Healthcare industry. We intend to modify our online
  marketplace and community to focus on healthcare professionals and those in need of individual at-home and post-operative care,
  together with Hospitals and physicians who need part time or additional personnel due to expansion. With this as one form of entry
  into the Healthcare space we will ultimately transform the company into a biomedical company, initially focused on advancing human
  organ transplant and tissue repair technology, and medical research which could potentially eliminate the need for organ or tissue
  match and anti-rejection drugs.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  GandTex technology was developed through 15 years of committed research. The results of the most recent Animal Trials conducted
  outside the U.S. indicate that this technology may produce dramatic breakthroughs in hematopoietic research and transplant techniques.
  The goal of the research was to address the issues of organ compatibility and the need for anti-rejection drugs in the donor.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  procedure itself, in its simplified format, follows six (6) steps: First the organ is removed, or the donor organ is examined.
  Then the Organ is put through a decellularization processes to isolate the extracellular matrix (ECM) of a tissue from its inhabiting
  cells, leaving an ECM scaffold of the original tissue. Specific cells are then harvested from bone marrow of the intended recipient.
  Following the bone marrow harvest the Particular hematopoietic cells are used in the process as well as a novel procedure involving
  temperature and pressure factors (under vacuum). As a result of the vacuum process, specific cells are released from platelets
  without complete platelet degranulation. The negative pressure created by the vacuum pulls the growth factors out of the platelets
  and into the plasma. Once processed, the cells are reintroduced into the recipient influencing further growth of an already implanted
  and recellularized organ. In addition to eliminating the need for tissue matching between donor and recipient, the NuLife Technique
  may have the potential to limit or eliminate the need for anti-rejection drugs.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Beginning
  over 3 years ago Pilot Studies were conducted: initially the 1<SUP>st</SUP>&nbsp;surgery was conducted in Ecuador, with 3 additional
  animal surgeries, one in the United States. Each study involved 2-3 animals per surgery, and all but one &ndash; unknown to the
  study group and the surgeons involved - had a virus prior to the transplant surgery, and did not pass the post-operative examination.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In
  the U.S. ~31,000 organ transplants occur every year but there are ~123,000 people on the candidate waiting list for a
  transplant. 22 people die each day in America waiting for transplants that can&rsquo;t take place because of the shortage of
  donated organs, due to failed tissue matches. Additionally, the average costs of the immunosuppressive drugs is approximately
  $17,000 per year (Medicare only covers the first three years): and these drugs can also cause increased infection and cancer
  rates - ultimately destroying the transplanted organ and other organs. Further, even with the immunosuppression medication,
  an individual recipient of an organ with the correct tissue match can still suffer rejection.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Kidney
  transplants will be the Company&rsquo;s initial target market as most common transplants &ndash; about 18,000 in 2015 &ndash; are
  Kidney transplants; most Kidney transplants patients spend years on dialysis while waiting; many Kidney transplants never receive
  the actual transplant due to the failure in finding the proper tissue match; and, all current Kidney transplant patients require
  anti-rejection drugs.</P>
  
  
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">It is our intention, and hope, that the GandTex technology
  will enable us to change the face of organ transplantation as we know it today. This expectation, which has only been conducted
  in animal trials outside the United States to date, resulted in the recipient animals not having to have tissue match and eliminated
  the need for anti-rejection drugs post-surgery.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">What
  this means to the individual in need of an organ transplant, a Kidney for example, is that the individual will no longer have to
  wait, often for years, for a matched organ or have to endure the expensive anti-rejection drugs following the replacement. And,
  for Kidney transplants, if our human trials are successful and he FDA approves the procedure, the recipients will no longer have
  to rely dialysis while waiting for a match, or have a need for dialysis post-transplant. If successful during pre-clinical and
  clinical trials, and approved for public use we intend to brand the technology as the &ldquo;NuLife Process&rdquo;.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 26 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Commercialization
  of the NuLife Process requires successful completion of a series of pre-clinical and clinical trials, as well as the demonstration
  of the reproducibility of the process. The steps include but are not limited to pre-clinical studies, defining the Chemistry, Manufacturing
  and Controls (CMC), documentation and necessary support about the process, and an escalating series of studies (Phase I, II and
  III) helping define the safety and efficacy of this process. These data will be evaluated by the FDA and/or other similar health
  authority. If authorization for marketing is granted, the Company plans to work with the existing Organ Procurement Organization
  (OPO) and major transplant centers to form a network of regional facilities capable of executing the process. In addition, Phase
  IV studies are commonly required for ongoing evaluations of safety and efficacy. In parallel with the development, health economics
  analyses will be conducted, in order to support the ultimate need for reimbursement in the markets it is made available.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
  Company will routinely assess options for developing and commercializing the NuLife Process, which could include development or
  marketing partnerships, licensing of alternate potential uses, or collaborations with existing companies in the transplant field.
  Further, the Company intends to vigorously pursue non-dilutive grants to aid in the development process.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The preparation
  of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States
  of America requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses
  and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined
  a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition
  and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result
  of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable
  under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 -
  &quot;Summary of Accounting Policies&quot; to the Financial Statements contained in this Quarterly Report certain critical accounting
  policies that affect the more significant judgments and estimates used in the preparation of the financial statements<B>.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Going Concern</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Our auditor has
  issued a &quot;going concern&quot; qualification as part of its opinion in the Audit Report for the fiscal year ended September
  30, 2016, and our financial statements as of and for the year then ended include a &quot;going concern&quot; footnote (See Footnote
  3 &ndash; Going Concern) disclosing that our ability to continue as a going concern is contingent on us to be able to raise working
  capital to generate revenue by completing and launching our online marketplace and community portal and implementing the new business
  strategy of developing the NuLife Process.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operation</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Three Months Ended June 30, 2017
  and 2016</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Revenue was $0
  for the three months ended June 30, 2017 and 2016.</P>
  
  
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Sales</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Cost of sales
  was $0 for the three months ended June 30, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative Expenses</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">General and administrative
  expenses and related party compensation were $199,964 and $51,228 for the three months ended June 30, 2017 and 2016, respectively.
  Expenses for the three months ended June 30, 2017 consisted primarily $171,166 for professional fees and related party compensation.
  Expenses for the three months ended June 30, 2016 consisted primarily of $50,717 for professional fees.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 27 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest
  expense was $84,989 and $2,699 for the three months ended June 30, 2017 and 2016, respectively, which related to interest
  accrued on borrowings, which were greater in the fiscal period ended June 30, 2017 as a result of newly issued debt in during
  October, November and December 2016 and June 2017. Included in interest expense for the three months ended June 30, 2017, was
  also $66,623 of non-cash interest expense related to the amortization of the debt discount.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Loss on derivative</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company recorded
  a net loss on derivative in the amount of $42,903 in the three months ended June 30, 2017. There was no derivative loss during
  the three months ended June 30, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Income</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest income
  was $2 and $-0- for the three months ended June 30, 2017 and 2016, respectively, which related to interest from bank accounts.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Nine Months Ended June 30, 2017
  and 2016</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Revenue was $0
  for the nine months ended June 30, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Sales</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Cost of sales
  was $0 for the nine months ended June 30, 2017 and 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>General and Administrative Expenses</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">General and administrative
  expenses and related party compensation were $3,433,027 and $228,637 for the nine months ended June 30, 2017 and 2016, respectively.
  Expenses for the nine months ended June 30, 2017 consisted primarily of $2,500,000 of non-cash stock based compensation of Preferred
  B shares regarding the GrandTex acquisition, $836,773 for professional fees and related party compensation. Expenses for the nine
  months ended June 30, 2016 consisted primarily of $216,068 for professional fees which included $43,098 of non-cash stock-based
  compensation expense and $60,000 for investor relations expense.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest expense
  was $204,583 and $6,991 for the nine months ended June 30, 2017 and 2016, respectively, which related to interest accrued on borrowings,
  which were greater in the fiscal period ended June 30, 2017 as a result of newly issued debt in during October, November and December
  2016 and June 2017. Included in interest expense for the nine months ended June 30, 2017, was also $159,173 of non-cash interest
  expense related to the amortization of the debt discount.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Loss on derivative</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The Company recorded
  a net loss on derivative in the amount of $39,579 in the nine months ended June 30, 2017. There was no derivative loss during the
  nine months ended June 30, 2016.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Income</I></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Interest income
  was $667 and $-0- for the nine months ended June 30, 2017 and 2016, respectively, which related to interest due on notes receivable
  and interest earned in bank accounts, which were greater in the fiscal period ended June 30, 2017 as a result of the two notes
  receivable issued.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 28 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">The following
  is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the nine months
  ended June 30, 2017 and 2016:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="width: 58%; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Activities</FONT></TD>
      <TD STYLE="width: 8%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 12%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(669,810</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
      <TD STYLE="width: 7%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="width: 11%; text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,260</FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing Activities</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;&nbsp;&nbsp;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,400</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing Activities</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">763,000</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,500</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
      <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Effect on Cash</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,190</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
      <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,160</FONT></TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Since acquiring
  the business plan and website, most of our resources and work have been devoted to our online marketplace and community portal,
  that is, planning our business, web site development, mobile application development, and implementing systems and controls. However,
  this has been suspended for the time being. When those procedures are completed, which we believe will occur over several month
  period following the receipt of adequate financing, we will primarily work on our intended service offerings as well further internal
  development of software for which we have developed our initial framework of and completed some coding. We believe that the work
  needed to initiate and complete the software development for our online marketplace and community portal, attract developers, and
  initiate our marketing plans, including the development of a saleable product suite, may be in excess of $100,000 if outside contractors
  and experts are used. If we are able to secure funding to outsource these procedures, of which there are no assurances, we will
  then commence the launch of our intended services and software products to the public. If we are able to use internal resources
  only (primarily consisting of the services of our president and chief financial officer), the process will take much longer and
  our initial launch may be limited to a much smaller target market. If we are unable to raise any funds from third party sources,
  the development costs would have to be funded by (i) Mr. Brian Loiselle, to whom we issued three notes for funds totaling $74,500,
  or (ii) our president and chief financial officer to the extent that they are capable and willing to provide such funds. While
  we have previously engaged the services of an established software development firm which we used on an as &quot;needed basis&quot;,
  their involvement is limited by our ability to raise financing. Our goal would be to have software products available, services
  available, multiple sales channels and a comprehensive corporate website up and running within one year after receipt of adequate
  financing, but there is no way of estimating what the likelihood of achieving that goal would be.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 21,750,000 shares of our common stock to its founder,
  Derek Cahill, as consideration for the purchase of a business plan along with a website. The acquisition of the business plan and
  website was valued at $72,500. To date, we have sold 5,400,000 shares of our common stock at $0.003 per share for $18,000 through
  a private placement and we sold 1,735,800 shares of our common stock at $0.042 per share for total gross proceeds of $72,325 through
  a public placement.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">If a market for
  our shares ever develops, of which there can be no assurances, we may continue to use restricted shares of our common stock or
  stock options to compensate employees/consultants and independent contractors wherever possible. We cannot predict the likelihood
  or source of raising capital or funds that may be needed to complete the development of our business plan and its stages as outlined
  above.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As a public company,
  we will incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual
  reports and proxy statements, if required. We estimate that these costs will range up to $50,000 per year over the next few years
  and may be significantly higher if our business volume and transactional activity increases, and we would not be subject to the
  requirements of Section 404 of the Sarbanes-Oxley Act of 2002 for an opinion on our system on internal controls by our independent
  audit firm unless and until we exceed $75 million in market capitalization. These obligations may reduce our ability and resources
  to expand our business plan and activities. We hope to be able to use our status as a public company to increase our ability to
  use noncash means of settling outstanding obligations (i.e. issuance of restricted shares of our common stock) and compensate independent
  contractors who provide professional services to us, although there can be no assurances that we will be successful in any of these
  efforts. We will also reduce compensation levels paid to management (if we attract or retain outside personnel to perform this
  function) if there is insufficient cash generated from operations to satisfy these costs.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 29 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We are presently
  seeking equity and debt financing for both segments of our business. However, these actions, if successful, could result in dilution
  of the ownership interests of existing shareholders and further dilute common stock book value, and such dilution may be material.
  The Company may offer shares of its common stock to settle a portion of the professional fees incurred in connection with its registration
  statement. No negotiations have taken place with any professional and no assurances can be made as to the likelihood that any professional
  will accept shares in settlement of obligations due them.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, we owed $544,075 in accounts payable, accrued expenses and to related parties, a substantial portion of which are past due.
  The only formal agreements, written or oral, with any vendors or other providers for payment of services or expenses are with respect
  to (i) contracted investor relation services, (ii) contracted services of the Company's former chief operating officer and (iii)
  compensation to the Company's president and chief financial officer and a consultant, one of whom is a director. There are no other
  significant liabilities at June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, the Company had one note payable issued and outstanding with a total principle of $25,000 and accrued interest of $14,400.
  The note was due on June 30, 2015, and has an interest rate of 12%. The note remains unpaid and is in default as of June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, the Company had three notes payable issued and outstanding with a former related party with a total principle of $74,500
  and accrued interest of $10,611. The three notes are due on the earlier of one week after the closing of a certain contemplated
  farm property acquisition or July 31, 2016, and have an interest rate of 10%. The related party for all three notes is East West
  Secured Developments, LLC, an Arizona Limited Liability Company (&ldquo;EWSD&rdquo;) of which Mr. Brian Loiselle is a managing
  member. On June 30, 2016, the Company entered into Amendment #1 to these three notes to extend the due date to the earlier of one
  week after the closing of the contemplated farm property acquisition or October 31, 2016. The acquisition of the various farm properties
  offered by Mr. Loiselle never occurred, and on August 26, 2016 Mr. Loiselle was notified that his relationship with the Company
  was terminated. Following that notice EWSD made a demand in October 2016 for repayment of the subject loans and subsequently declared
  the notes in default. The default interest demand of 18% by Mr. Loiselle is being disputed by the Company due to the lack of provision
  for default interest in the notes.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">As of June 30,
  2017, the Company had twenty convertible notes payable issued and outstanding with a total principle of $863,025 and accrued interest
  of $43,284. The notes are due December 31, 2017 through December 22, 2019 and have interest rates of 8% to 12%. The notes remain
  unpaid as of June 30, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Letters of Intent</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="background-color: white">On
  April 24, 2015, the Company signed a non-binding Letter of Intent (&quot;LOI&quot;) with a licensed cultivator to provide turnkey
  operations and services to a 150,000-square foot licensed cultivation facility located in Pueblo, Colorado (the &quot;Tamarack
  Project&quot;). In connection therewith, the first phase of construction was expected to begin in June 2015, with cultivation expected
  begin in early July; however, none of these events have occurred as of the filing of this Annual Report on Form 10-K. Further progress
  with respect to this LOI was dependent on, among other matters, the Company obtaining the necessary financing to proceed. The promised
  financing did not materialize and, consequently, we officially terminate all Letters of Intent related to the Tamarack Project
  and a related proposed business venture with Generex Biotechnology Corporation.</FONT></P>
  
  
  
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><FONT STYLE="background-color: white">On
  September 13, 2016, we entered into a Letter of Intent with GandTex, the owner of patents covering new techniques for organ transplants
  and tissue repair. We entered into a definitive agreement with GandTex on October 3, 2016 and received assignments related to two
  (2) of the three (3) patents on November 30, 2016</FONT></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 30 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CRITICAL ACCOUNTING PRONOUNCEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our financial statements
  and related public financial information are based on the application of generally accepted accounting principles in the United
  States (&ldquo;GAAP&rdquo;). GAAP requires the use of estimates, assumptions, judgments and subjective interpretations of accounting
  principles that have an impact on the assets, liabilities, revenues and&nbsp;expense amounts reported. These estimates can also
  affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial
  condition. We believe our use of estimates and underlying accounting&nbsp;assumptions adhere to GAAP and are consistently and conservatively
  applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under
  the circumstances. Actual results may differ materially from&nbsp;these estimates under different assumptions or conditions. We
  continue to monitor significant estimates made during the preparation of our financial statements.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our significant
  accounting policies are summarized in Note 2 of our financial statements included in our September 30, 2016 Form 10-K. While all
  of these significant accounting policies impact our financial condition and results of operations, we view certain of these policies
  as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements
  and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management
  believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies
  would cause a material effect on our&nbsp;results of operations, financial position or liquidity for the periods presented in this
  report.&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue Recognition</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We recognize revenue on arrangements
  in accordance with FASB ASC No. 605, &ldquo;Revenue Recognition&rdquo;.&nbsp;&nbsp;In all cases, revenue is recognized only when
  the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability
  of the resulting receivable is reasonably assured.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>RECENT ACCOUNTING PRONOUNCEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We have reviewed accounting pronouncements
  issued during the past two years and have adopted any that are applicable to the Company. We have determined that none had a material
  impact on our financial position, results of operations, or cash flows for the periods presented in this report.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OFF-BALANCE SHEET ARRANGEMENTS</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">We do not have any off-balance sheet
  arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &ldquo;special purpose
  entities&rdquo; (&ldquo;SPE&rdquo;s).</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><B>Item 3. Quantitative and
  Qualitative Disclosures about Market Risks</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Not applicable because we are a smaller
  reporting company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_005"></A>Item 4. Controls
  and Procedures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Evaluation of Disclosure Controls
  and Procedures&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Pursuant to Rule 13a-15(b) under the
  Securities Exchange Act of 1934 (&ldquo;Exchange Act&rdquo;), the Company carried out an evaluation, with the participation of
  the Company&rsquo;s management, including the Company&rsquo;s President (the &ldquo;President&rdquo;) and principal Financial Officer,
  of the effectiveness of the Company&rsquo;s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange
  Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&rsquo;s President and principal
  financial officer concluded that the Company&rsquo;s disclosure controls and procedures were not effective to ensure that information
  required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed,</P>
  
  
  <!-- Field: Page; Sequence: 31 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">summarized and reported, within the
  time periods specified in the SEC&rsquo;s rules and forms, and that such information is accumulated and communicated to the Company&rsquo;s
  management, including the Company&rsquo;s President and principal financial officer, as appropriate, to allow timely decisions
  regarding required disclosure as a result of continuing material weaknesses (such as the absence of an audit committee and absence
  of qualified independent directors) in its internal control over financial reporting.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in Internal Controls Over
  Financial Reporting</I></B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">There have been no changes in the Company's
  internal control over financial reporting during the latest fiscal quarter that have materially affected, or are reasonably likely
  to materially affect, the Company's internal control over financial reporting.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 32 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_006"></A>PART II - OTHER INFORMATION</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_007"></A>Item 1. Legal Proceedings.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company owes
  on promissory notes that have an aggregate principal amount of $74,500 and are simple promissory notes with 10% annual interest
  to EWSD. The notes are in default, but there is not a default interest provided in the notes. Therefore, the notes continue to
  accrue interest at 10% per annum until paid or collected. Mr. Loiselle is demanding 18% per month interest for the past four months
  to the present. The Company has disputed this interest that is not detailed on the notes. Furthermore, Mr. Loiselle is claiming
  unpaid compensation of $10,000 per month for services without an agreement with the Company. These charges are also being disputed
  by the Company. These disputes represent a material risk, and may be litigated in the future other than the aforementioned, the
  Company currently has no other litigation pending, threatened or contemplated, or unsatisfied judgments.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time,
  we are also a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our
  rights under contracts with contractors and suppliers. While the outcome of these legal proceedings cannot at this time be predicted
  with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of
  operations.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_008"></A>Item 1A. Risk Factors</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">Not applicable because we are a smaller
  reporting company.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_009"></A><B>Item 2. Unregistered Sales of Equity
  Securities and Use of Proceeds</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 7,250,00 shares of our common, now 21,750,000 shares
  following the 3:1 forward stock split, stock to its founder, Derek Cahill, as consideration for the purchase of a business plan
  along with a website. The acquisition of the business plan and website was valued at $72,500.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 29, 2013,
  the Company completed a private placement whereby it issued 5,400,000 shares of common stock to accredited investors at $0.003
  per share for total gross proceeds of $18,000.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 16, 2014,
  the Company completed a public offering whereby it issued 1,735,800 shares of common stock at $0.042 per share for total gross
  proceeds of $72,325. The Company's Registration Statement on Form S-1 was declared effective March 6, 2014.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of the grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vest over a six-month period, with the vested shares recorded on the accompanying balance sheet under equity - shares to be issued.
  The subject 100,000 shares of common stock will be issued in a subsequent period.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company amended
  and restated that certain outstanding promissory note of the Company, dated July 3, 2015, and in the principal amount of $50,025
  (the &quot;Default Note&quot;). The replacement convertible promissory note (the &ldquo;Exchange Note&rdquo;) matures on December
  31, 2017 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 8% per annum, and the principal and interest due
  thereunder may be prepaid at any time. The Exchange Note, together with all interest as accrued, is convertible into shares of
  the Company&rsquo;s common stock at $0.11, which amount represents the average trailing average high closing Ask price of the Company&rsquo;s
  common stock as of the date of issuance of the Exchange Note.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2,
  2016, the Company entered into those certain Note Purchase Agreements (collectively, the &ldquo;Purchase Agreements&rdquo;) in
  connection with the issuance of certain convertible promissory notes (collectively, the &ldquo;Purchase Notes&rdquo;) in the aggregate
  principal amount of $50,000. All of the Purchase Notes mature thirty-six months from the date of issuance (the &ldquo;Maturity
  Date&rdquo;), and bear interest at the rate of 10% per annum. Each of the Purchase Notes may be prepaid until the Maturity Date
  at 110% of the principal and interest amount outstanding. The Purchase Notes, together with all interest as accrued, are each convertible
  into shares of the Company&rsquo;s common stock at 50% of the trailing average highest closing bid price of the Company&rsquo;s
  common stock on the date of conversion. The Purchase Agreements and the Purchase Notes contain representations, warranties, conditions,
  restrictions, and covenants of the Company that are customary in such transactions with smaller companies.</P>
  
  <!-- Field: Page; Sequence: 33 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Also on September
  2, 2016, the Company amended and restated the Default Note. The Exchange Note matures on December 31, 2017, and bears interest
  at the rate of 8% per annum, and the principal and interest due thereunder may be prepaid at any time. The Exchange Note, together
  with all interest as accrued, is convertible into shares of the Company&rsquo;s common stock at $0.11, which amount represents
  the average trailing average high closing Ask price of the Company&rsquo;s common stock as of the date of issuance of the Exchange
  Note.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&emsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Notes
  may be accelerated by the holders thereof in the event of default. In addition, the amounts due and payable under the Purchase
  Notes (and, consequently, the number of shares of common stock convertible thereunto) may be increased to 150% of the principal
  and interest amounts of the Purchase Notes. The Purchase Notes are a direct financial obligation of the Company and are considered
  a current liability of the Company for accounting purposes.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We relied upon Section
  4(2) of the Securities Act of 1933, as amended for the above private placement issuances. We believed that Section 4(2) was available
  because:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;None of
  these issuances involved underwriters, underwriting discounts or commissions</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#9;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;We placed
  restrictive legends on all certificates issued</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#9;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;No sales
  were made by general solicitation or advertising</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#9;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Sales were
  made only to accredited investors</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
  the above transactions, we provided the following to all investors:</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Access to
  all our books and records</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#9;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;Access to
  all material contracts and documents relating to our operation</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&#9;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&bull;&#9;The opportunity
  to obtain any additional information, to the extent we possessed such information, necessary to verify the accuracy of the information
  to which the investors were given access.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Pursuant
  to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board approved the issuance of 10,000,000 shares
  of the Company&rsquo;s Series B Convertible Preferred Stock to GandTex. The shares were released to GandTex concurrent with the
  closing on January 29, 2017. </FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the &ldquo;Conversion Agreement&rdquo;) in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC(&ldquo;MZ&rdquo;) by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the &ldquo;Debt&rdquo;) together with a release by MZ in favor of the
  Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of fees or
  costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the Conversion
  Agreement, the Company issued to MZ an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  February 28, 2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.(&ldquo;Global&ldquo;), a
  Company owned by the Company&rsquo;s President Fred G. Luke (&ldquo;the &ldquo;Global Agreement&rdquo;), pursuant to which the
  Company retained Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve
  as the Company&rsquo;s President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing
  of the Company&rsquo;s its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received
  an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
  June 26, 2017, the Company entered into a Securities Purchase Agreement (&ldquo;June SPA&rdquo;) in connection with the issuance
  of a convertible promissory note (&ldquo;June Note&rdquo;) in the aggregate principal amount of $78,000. The June Note matures
  on June 30, 2018 (the &ldquo;Maturity Date&rdquo;), and bears interest at the rate of 12% per annum. After 180 days, the June Note
  may not be prepaid. Any amount of principal or interest on the June Note which is not paid when due shall bear interest at the
  rate of twenty two percent (22%) per annum from the due date. The June Note, together with all interest as accrued, is convertible
  into shares of the Company&rsquo;s common stock at a 35% discount to</P>
  
  
  <!-- Field: Page; Sequence: 34 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">the lowest
  trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion Date. The June SPA and the
  June Note contain representations, warranties, conditions, restrictions, and covenants of the Company that are customary in such
  transactions with smaller companies, and the SPA and June Note were attached as Exhibits to our Form 8-K filed on July 27, 2017.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_010"></A><B>Item 3. Defaults Upon Senior Securities.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_011"></A><B>Item 4. Mine Safety Disclosures</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Not Applicable.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_012"></A>Item 5. Other Information.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 35 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><A HREF="#TableOfContents" TITLE="Table of Contents" STYLE="font-style: italic">Table of Contents</A>&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_013"></A><B>Item 6. Exhibits.</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
      <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
      <TD STYLE="width: 90%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #CCEEFF">3.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">Articles of Incorporation(1)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">3.2</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">Bylaws(1)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex311_302certification.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex321_906certification.htm">Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">(1) Incorporated herein by reference to the Company's Form 10-Q filed with the Securities and Exchange Commission
  on February 21, 2017.</P>
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  <HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">
  
  <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_014"></A><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
  duly authorized.</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NuLife Sciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="line-height: 115%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 62%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
      August 14, 2017</FONT></TD>
      <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
      <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp; Fred Luke</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fred Luke</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD>
      <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
  </TABLE>
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 36; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>
  
  
  
  <P STYLE="margin: 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "10-Q", "sequence": "1", "filename": "f10q_nulife063017.htm", "description": "FORM 10-Q", "secsgml_size_bytes": 397737}]
metadata_filer: {"company-data": {"conformed-name": "NuLife Sciences, Inc.", "cik": "0001592603", "assigned-sic": "7310", "irs-number": "463876675", "state-of-incorporation": "NV", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "000-55805", "film-number": "171037155"}, "business-address": {"street1": "1031 CALLE RECODO, SUITE B", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673", "phone": "949-973-0684"}, "mail-address": {"street1": "1031 CALLE RECODO, SUITE B", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673"}, "former-company": {"former-conformed-name": "SmooFi, Inc.", "date-changed": "20131121"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 10-Q
  (Mark One)
  ☒
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
  For the quarterly period ended June 30, 2017
  ☐
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
  For the transition period from ______to______
  Commission File Number:
  000-54163
  NuLife Sciences, Inc.
  (Exact name of registrant as specified in its Charter)
  Nevada
  46-3876675
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employee Identification No.)
  2618 San Miguel, Suite 203
  Newport Beach, CA
  92660
  (Address of principal executive office)
  (Zip Code)
  (949) 973-0684
  (Registrant's telephone number,
  including area code)
  Not Applicable
  (Former Name, former address
  and former fiscal year, if changed since last report)
  Indicate
  by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
  Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and
  (2) has been subject to such filing requirements for the past 90 days.
  Yes
  ☒
  No
  ☐
  Indicate
  by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
  Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
  preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes
  ☒
  No
  ☐
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
  of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule
  12b-2 of the Exchange Act:
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer (Do not check if smaller reporting company)
  ☐
  Smaller reporting company
  ☒
  Table of Contents
  Indicate
  by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes
  ☒
  No
  ☐
  Indicate the number of shares
  outstanding of each of the issuer's classes of common stock as of the latest practicable date: As of July 31, 2017,
  there were
  37,261,049
  shares of $0.001 par value common stock, issued and
  outstanding.
  2
  Table of Contents
  PART I: FINANCIAL INFORMATION
  Item 1: Financial Statements
  4
  Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operation
  25
  Item 3: Quantitative and Qualitative Disclosures about Market Risk
  31
  Item 4: Controls and Procedures
  31
  PART II: OTHER INFORMATION
  Item 1: Legal Proceedings
  33
  Item 1A: Risk Factors
  33
  Item 2: Unregistered Sales of Equity Securities and Use of Proceeds
  33
  Item 3: Defaults Upon Senior Securities
  3
  5
  Item 4: Mine Safety Disclosures
  35
  Item 5: Other Information
  35
  Item 6: Exhibits
  36
  SIGNATURES
  36
  3
  Table of Contents
  PART I - FINANCIAL INFORMATION
  ITEM 1.  FINANCIAL STATEMENTS
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Consolidated Balance Sheets
  June 30, 2017 (Unaudited)
  September 30, 2016
  ASSETS
  CURRENT ASSETS:
  Cash
  $
  94,276
  $
  1,086
  Note receivable
  —
  25,241
  Total Current Assets
  94,276
  26,327
  Security deposit
  4,871
  —
  TOTAL ASSETS
  $
  99,147
  $
  26,327
  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
  CURRENT LIABILITIES:
  Accrued expenses
  $
  492,135
  $
  448,859
  Due to related parties
  52,500
  65,000
  Accrued interest
  68,295
  22,885
  Notes payable
  99,500
  99,500
  Convertible note, current portion, net of debt discount of $94,958 and $-0-
  33,067
  —
  TOTAL CURRENT LIABILITIES
  745,497
  636,244
  Convertible notes, net of debt discount and beneficial conversion feature of $34,794 and $91,480 and $516,100 and $-0-, respectively
  184,106
  8,545
  Derivative liability
  283,800
  169,221
  TOTAL LONG TERM LIABILITIES
  467,906
  177,766
  TOTAL LIABILITIES
  1,213,403
  814,010
  STOCKHOLDERS' EQUITY (DEFICIT):
  Preferred stock Series A, $0.001 par value; 15,000,000 shares authorized; 110,000 issued or outstanding
  110
  —
  Preferred stock Series B, $0.001 par value; 10,000,000 shares authorized; 10,000,000 issued or outstanding
  10,000
  —
  Common stock, $0.001 par value; 475,000,000 shares authorized; 31,085,800 shares issued and outstanding respectively
  31,086
  31,086
  Additional paid in capital
  3,732,578
  392,739
  Accumulated deficit
  (4,888,030
  )
  (1,211,508
  )
  TOTAL STOCKHOLDERS' EQUITY (DEFICIT)
  (1,114,256
  )
  (787,683
  )
  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
  $
  99,147
  $
  26,327
  Share and per share amounts
  have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.
  The accompanying notes are
  an integral part of these financial statements.
  4
  Table of Contents
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Consolidated Statements
  of Operations
  For the Three and Nine
  Months Ended June 30, 2017 and 2016
  (Unaudited)
  Three Months Ended June 30,
  Nine Months Ended June 30,
  2017
  2016
  2017
  2016
  Revenue
  $
  —
  $
  —
  $
  —
  $
  —
  Cost of sales
  —
  —
  —
  —
  Gross Profit
  —
  —
  —
  —
  Operating expense:
  General and administrative expenses
  (199,964
  )
  (51,228
  )
  (3,433,027
  )
  (228,637
  )
  Total operating expense
  (199,964
  )
  (51,228
  )
  (3,433,027
  )
  (228,637
  )
  Loss from operations
  (199,964
  )
  51,228
  )
  (3,433,027
  )
  (228,637
  )
  Interest expense
  (84,989
  )
  (2,699
  )
  (204,583
  )
  (6,991
  )
  Interest income
  2
  —
  667
  —
  Loss on change in fair value of derivative and derivative expense
  (42,903
  )
  —
  (39,579
  )
  —
  Loss before provision for income tax
  (327,854
  )
  (53,927
  )
  (3,676,522
  )
  (235,628
  )
  Provision for income taxes
  —
  —
  Net loss
  $
  (327,854
  )
  $
  (53,927
  )
  $
  (3,676,522
  )
  $
  (235,628
  )
  Basic and diluted loss per share
  $
  (0.01
  )
  $
  (0.00
  )
  $
  (0.12
  )
  $
  (0.01
  )
  Weighted average common shares outstanding – basic and diluted
  31,085,800
  31,085,800
  31,085,800
  30,634,561
  Share and per share amounts
  have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.
  The accompanying notes are
  an integral part of these financial statements.
  5
  Table of Contents
  NuLife Sciences, Inc.
  (fka "SmooFi, Inc.")
  Consolidated Statement of Cash Flows
  For the Nine Months Ended
  June 30, 2017 and 2016
  (Unaudited)
  2017
  2016
  CASH FLOW FROM OPERATING ACTIVITIES:
  Net loss
  $
  (3,676,522
  )
  $
  (235,628
  )
  Adjustments to reconcile net loss to net cash used in operating activities:
  Amortization of debt discount
  81,173
  —
  Gain on change in fair value of derivative and derivative expense
  114,579
  —
  Stock-based compensation expense
  2,700,654
  43,098
  Bad debt on note receivable
  25,904
  —
  Prepaid expenses
  —
  3,165
  Note receivable
  (663
  )
  (1,437
  )
  Security deposit
  (4,871
  )
  —
  Accounts payable and accrued expenses
  57,026
  27,925
  Due to related party
  (12,500
  )
  134,200
  Accrued interest payable
  45,410
  8,417
  Net Cash Used in Operating Activities
  (669,810
  )
  (20,260
  )
  CASH FLOW USED BY INVESTING ACTIVITIES:
  Deposit on farm property
  —
  (25,000
  )
  Loan to sellers of farm property
  —
  (31,400
  )
  Net Cash Used by Investing Activities
  —
  (56,400
  )
  CASH FLOW FROM FINANCING ACTIVITIES:
  Loan proceeds
  —
  74,500
  Proceeds from the issuance of convertible notes
  763,000
  —
  Net Cash Provided by Financing Activities
  763,000
  74,500
  CHANGE IN CASH
  93,190
  (2,160
  )
  CASH AT BEGINNING OF PERIOD
  1,086
  2,160
  CASH AT END OF PERIOD
  $
  94,276
  $
  —
  SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
  Cash paid for:
  Interest
  $
  —
  $
  —
  Income taxes
  $
  —
  $
  —
  The accompanying notes are
  an integral part of these financial statements.
  6
  Table of Contents
  NULIFE SCIENCES, INC. AND SUBSIDIARIES
  NOTES TO FINANCIAL STATEMENTS
  JUNE 30, 2017 and 2016
  (Unaudited)
  NOTE 1 - ORGANIZATION
  NuLife Sciences
  Inc., formerly SmooFi, Inc. (the "Company") was incorporated under the laws of the State of Nevada on October 15, 2013.
  The Company issued 7,250,000 shares of its common stock to our founder, Derek Cahill, as consideration for the purchase of a business
  plan along with a website.
  On April 21, 2015, the Board of Directors of the Company
  approved a three-for-one forward stock split of the Company's common stock (the "Forward Split"). Accordingly, shareholders
  owning shares of the Company's common stock received two additional shares of the Company for each share they owned, and Mr. Cahill's
  7,250,000 shares became 21,750,000 shares. Prior to the Forward Split the Company had 10,128,600 shares issued and outstanding
  and following the Forward Split the Company has 31,085,800 shares issued and outstanding.
  Online marketplace
  and community
  The Company's
  initially-defined business strategy is to acquire and/or develop and market software and services that will significantly enhance
  the performance and functionality of the Internet services used by individuals and by small to medium sized businesses. The Company's
  products and services, essentially an online marketplace and community, will use proprietary technology that will enable users,
  both service requestors and service providers, to work collaboratively to obtain substantial improvements in performance, reliability
  and usability. Service requestors (people or companies requesting a service) name their own price, date and time for any service.
  A service requestor can also select qualifying criteria such as number of reviews or review rankings of a service provider. The
  first service provider who can provide that service, on that date, at that time and meets the service ranking requirements will
  get the project. The web site and the platform, originally titled www.AnytimeJobs.com experienced security issues shortly after
  it was launched and had to be taken down to correct the security problems. At the present time, the additional programming to eliminate
  the security problem has not been completed and the platform is not available online.
  Once the security
  issues with the platform are resolved, the Company's online marketplace and online community will match up daily job or service
  requests and fill market demand for service requests throughout a particular local community, county or city and will connect local
  resources with local needs. A goal is to create jobs and provide market value for basic services by aggregating these low-cost
  services within each local market. This will maximize value for either the person or company requesting the service and for the
  person or company providing the service. In other words, service providers will get the best possible price for their service and
  the party requesting the service will pay the lowest possible price.
  Operations,
  Consulting and Advisory Services in the Organ Transplant segment of the Healthcare Industry
  On November 1, 2016,
  pursuant to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the assets of GandTex LLC,
  A Texas Limited Liability Company ("GandTex"), the Company formed 2 subsidiaries in the state of Nevada, NuLife BioMed,
  Inc., and NuLife Technologies, Inc. GandTex is a biomedical company focused on advancing human organ transplant technology and
  medical research. The assets being transferred consist of certain proprietary patents for eliminating the need for an
  organ or tissue match, and the necessity for anti-rejection drugs, as well as management of, and historical data for, animal trials
  conducted by GandTex.
  On January 29, 2017,
  the Company announced the completion of an Asset Purchase Agreement to acquire all of the assets (the "Asset Purchase")
  of GandTex was the owner of certain patents and licensed rights related to biomedical company focused on advancing human organ
  transplant technology and medical research. The assets consisted of certain proprietary patents for eliminating the need for an
  organ or tissue match, and the necessity for anti-rejection drugs, as well as management of, and historical data for, animal trials
  (the "Animal Trials") conducted by a third party operating under the GandTex Assets (collectively, the "GandTex
  Assets"). Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the Company agreed to
  provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the GandTex Assets, the Company
  issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by a single individual
  Managing Member who beneficially owns 70% of GandTex. The Asset Purchase was approved by a majority of the Company's disinterested
  directors.
  7
  Table of Contents
  On June 26, 2017,
  the Company's wholly owned subsidiary, NuLife Technologies Inc., formed and serves as the current Managing Member of NuLife
  Oncology Services LLC, a Wyoming limited liability company ("NuLife Ocnology").
  We intend to
  have NuLife Oncology operate as a stand-alone joint venture between NuLife Technologies Inc. as a Co-Managing Member and one
  other recognized consulting organization in the healthcare patient, clinical & genomic data collection, and
  the
  pharmaceutical / diagnostic industries serve as a Co-Managing Member. AS of the date of this Report we do not have any
  agreements or letters of Intent signed with the prospective Co-Managing Member.
  NuLife Oncology
  was created to address the Healthcare Professional Services Group focused on optimizing oncological data exchange for the pharmaceutical
  / diagnostic industries betterment of oncology patients, medical practices, and the pharmaceutical / diagnostic industries. It
  is our current intent to have NuLife Oncology focus on addressing the following Healthcare marketplace dynamics:
  o
  The capture and aggregation of large-scale patient clinical &
  genomic data sets within oncology practices is quickly advancing, while plans to optimize the utility of such data remains poorly-defined.
  Intuitively, the oncology practices recognize the value of such data, but lack the sophistication to create monetization plans
  with the data.
  o
  The exchange of genomic data between healthcare providers and pharma/diagnostic
  companies is nearly non-existent; significant opportunities exist to facilitate efficient Patient & Rx match both in pre-clinical
  and post-marketing settings. Through its network of oncology practices, NuLife
  Oncology
  will
  assimilate these data sources in order to "repackage and sell" to various oncology marketplace stakeholders.
  o
  There are no known corporate entities serving as data exchanges,
  which seek to benefit all contributors and consumers of these data. Data sale transactions are typically one-sided, whereas NuLife
  Oncology
  will serve as a "revenue sharing" partner with the oncology physician
  practices.
  o
  The proliferation of Targeted Therapies and Molecular Diagnostic
  tests presents various challenges re: integrating new technologies within oncology practices. NuLife
  Oncology
  will partner with practices to ensure seamless integration of current and emerging new technologies by effectively sourcing, contracting
  and intermediating molecular testing on the practice's behalf. NuLife
  Oncology
  will accomplish
  this through a preferred and recommended network of diagnostic testing companies. Management of this process will serve as "the
  gate" through which NuLife
  Oncology
  secures access to genomic and clinical data from
  the practices.
  In short, NuLife Oncology aims to solve the data-exchange
  gap through:
  o
  Democratization of appropriate low-cost diagnostic
  testing services
  o
  Integration of molecular data for improved patient
  outcomes
  o
  Brokering data relationships between Pharma and
  oncology practices
  o
  Monetization of data with benefit to all Oncology
  Care stakeholders
  o
  Creating genomics-based research opportunities
  for oncology practices
  8
  Table of Contents
  NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
  Basis of Presentation
  The Company's
  financial statements are prepared using the accrual method of accounting. The Company has elected a September 30 fiscal year-end.
  These financial statements present the consolidated financial statements of NuLife Sciences, Inc. and its two wholly owned subsidiaries,
  NuLife Biomed, Inc. and NuLife Technologies, Inc., and NuLife Oncologies LLC, a newly formed Wyoming limited liability company
  for which NuLife Technologies Inc. currently serves as the Managing Member.
  The unaudited
  interim financial statements have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission.
  The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are,
  in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information
  and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally
  accepted in the United States of America have been omitted pursuant to such rules and regulations. These condensed consolidated
  financial statements should be read in conjunction with the audited financial statements and notes for the year ended September
  30, 2016 included in our Annual Report on Form 10-K. The results of the nine-month periods ended June 30, 2017 are not necessarily
  indicative of the results to be expected for the full year ending September 30, 2017.
  Cash Equivalents
  For purposes of
  the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three months
  or less at the time of issuance to be cash equivalents. The Company does not have any cash equivalent as of June 30, 2017 and September
  30, 2016.
  Stock-based Compensation
  The Company
  follows ASC 718-10,
  Stock Compensation
  , which addresses the accounting for transactions in which an entity
  exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains
  employee services in share-based payment transactions. ASC 718-10 requires measurement of the cost of employee services
  received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited
  exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be
  recognized. The Company adopted a Non-Qualified Incentive Stock Compensation Plan pursuant to which the Company is reserving
  seven million (7,000,000) shares of Common Stock for issuance for services and the exercise of stock options. As of June 30
  ,2017 the Company has only issued one Stock Option for One Million Five Hundred Thousand (1,500,000) shares to its President,
  Fred G. Luke and has an agreement to issue One Million Five Hundred Thousand (1,500,000) shares to its CEO, John Hollister,
  but has not yet provided Mr. Hollister with the Option Agreement. Nonemployee share-based payments are measured at fair
  value, based on either the fair value of the equity instrument issued or on the fair value of the services received. We
  determine the fair value of common stock grants based on the price of the common stock on the measurement date (which is the
  earlier of the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, if
  there are sufficient disincentives to ensure performance, or the date at which the counterparty's performance is complete).
  We determine the fair value of preferred stock grants based on the price of the preferred stock as potentially converted into
  common stock and based on the underlying common stock on the measurement date (which is the earlier of the date at which
  a commitment for performance by the counterparty to earn the equity instruments is reached, if there are sufficient
  disincentives to ensure performance, or the date at which the counterparty's performance is complete).
  Use of Estimates and Assumptions
  Preparation of
  the financial statements in conformity with accounting principles generally accepted in the United States requires management to
  make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from
  those estimates. The Company has adopted the provisions of ASC 260.
  9
  Table of Contents
  Loss per Share
  The basic loss
  per share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common
  shares during the year. The diluted loss per share is calculated by dividing the Company's net loss available to common shareholders
  by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
  is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share
  are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.
  Fair Value Measurements and Disclosures
  Fair value estimates
  discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2017
  and 2016. The respective carrying value of certain on-balance-sheet financial instruments, approximate their fair values. These
  financial instruments include cash, accounts receivable, accounts payable, accrued expenses and notes payable. Fair values were
  assumed to approximate carrying values for these financial instruments because they are short term in nature and their carrying
  amounts approximate fair values or they are receivable or payable on demand.
  The Company uses
  fair value measurements under the three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure
  for fair value measures. The three levels are defined as follows:
  •
  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  •
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  •
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.
  Fair Value Measurements
  Using Fair Value Hierarchy
  Level 1
  Level 2
  Level 3
  Convertible notes (net of discount) – June 30, 2017
  $
  —
  $
  —
  $
  217,173
  Convertible notes (net of discount) – September 30, 2016
  $
  —
  $
  —
  $
  8,545
  Derivative liability – June 30, 2017
  $
  —
  $
  —
  $
  283,800
  Derivative liability – September 30, 2016
  $
  —
  $
  —
  $
  169,221
  The following table
  provides a summary of the changes in fair value of the Company's Promissory Notes, which are both Level 3 liabilities as
  of June 30, 2017:
  Balance at September 30, 2016
  $
  8,545
  Issuance of notes
  763,000
  Debt discount on convertible notes
  (78,000
  )
  Accretion of debt discount
  39,727
  Debt discount on convertible notes due to beneficial conversion feature
  (635,545
  )
  Accretion of debt discount due to beneficial conversion feature
  119,446
  Balance June 30, 2017
  $
  217,173
  The Company determined
  the value of its convertible notes using a market interest rate and the value of the derivative liability issued at the time of
  the transaction less the accretion. There is no active market for the debt and the value was based on the delayed payment terms
  in addition to other facts and circumstances at the end of June 30, 2017 and 2016.
  10
  Table of Contents
  Derivative Financial Instruments
  The Company evaluates
  our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
  For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
  its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
  For stock-based financial instruments, the Company uses the Black-Scholes-Merton pricing model to value the derivative instruments.
  The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity,
  is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current
  or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the
  balance sheet date.
  The classification
  of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at
  the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value
  of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current
  or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet
  date.
  The Company estimates
  the fair value of these instruments using the Black-Scholes option pricing model and the intrinsic value if the convertible notes
  are due on demand.
  We have determined
  that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price "reset"
  adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts
  in an Entity's Own Stock ("ASC 815-40"). Certain of the convertible debentures have a variable exercise price,
  thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares
  to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through
  earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as "Other income
  (expense) - gain (loss) on change in derivative liabilities." Please refer to Note 8 below.
  Income Taxes
  Income taxes are
  provided in accordance with ASC 740,
  Income Taxes
  . A deferred tax asset or liability is recorded for all temporary
  differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from
  the net change during the year of deferred tax assets and liabilities.
  Deferred tax assets
  are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of
  the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax
  laws and rates on the date of enactment.
  No provision was
  made for Federal or State income taxes.
  Advertising
  Advertising will
  be expensed in the period in which it is incurred. There have been no advertising expenses for the reporting periods presented.
  Intangible Assets
  Intangible assets
  with finite lives are amortized over their estimated useful life. The Company monitors conditions related to these assets to determine
  whether events and circumstances warrant a revision to the remaining amortization period. The Company tests its intangible assets
  with finite lives for potential impairment whenever management concludes events or changes in circumstances indicate that the carrying
  amount may not be recoverable. The original estimate of an asset's useful life and the impact of an event or circumstance on either
  an asset's useful life or carrying value involve significant judgment.
  11
  Table of Contents
  Reclassification
  In order to present
  comparable financial sheets, accrued expenses and due to related parties were reclassified as of September 30, 2016. This reclassification
  did not affect the amount of liabilities in total.
  Recently Issued Accounting Pronouncement
  s
  In August 2014,
  the FASB issued ASU No. 2014-15, "Presentation of Financial Statements — Going Concern (Subtopic 205-40), Disclosure
  of Uncertainties about an Entity's Ability to Continue as a Going Concern". Continuation of a reporting entity as a going
  concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent.
  Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently,
  there is no guidance under U.S. GAAP about management's responsibility to evaluate whether there is substantial doubt about an
  entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide
  that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments
  require management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles
  that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt,
  (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating
  effect of management's plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration
  of management's plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6)
  require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).
  In February 2016,
  the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840).
  ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments
  in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early
  application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or
  entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently
  evaluating the impact of this new standard on its consolidated financial statements.
  In March 2016,
  the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-09, "Compensation
  - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). The
  standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax
  impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods
  within those years, beginning after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the
  impact that the standard will have on its financial statements.
  The Company reviewed
  all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC and
  they did not or are not believed by management to have a material impact on the Company's present or future financial statements.
  NOTE 3 – GOING CONCERN
  The accompanying
  financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying
  financial statements, the Company had negative working capital of $651,221 and, having incurred net losses since inception, an
  accumulated deficit of $4,888,030 at June 30, 2017.
  For the period
  ended June 30, 2017, management evaluated the Company's ability to continue as a going concern and concluded that substantial doubt
  has not been alleviated about the Company's ability to continue as a going concern. While the Company continues to explore further
  significant sources of financing, management's assessment was based on the uncertainty related to the amount and nature of such
  financing over the next twelve months.
  The financial
  statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
  12
  Table of Contents
  NOTE 4 – NOTES RECEIVABLE
  On January 15,
  2016, the Company entered into a secured promissory note in the amount of $46,400 to advance funds to the sellers of certain farm
  property in Colorado the Company was seeking to purchase. Closing was subject to financing and other contingencies per a non-binding
  Letter of Intent. This note had an interest rate of 8% per annum, with principal and unpaid and accrued interest originally due
  on June 30, 2016. On March 31, 2016, the Company entered into Amendment #1 to this note to (i) extend the due date to June 30,
  2016, unless the contemplated transaction closes prior thereto, in which case the note will be cancelled, (ii) reduce the principal
  to $31,400 to characterize $15,000 of the funds transferred to sellers as a non-refundable earnest money payment and (iii) stipulate
  that interest is to accrue on the lower $31,400 principal since inception. On June 30, 2016, the Company entered into Amendment
  #2 to this note to (i) extend the due date to September 30, 2016, unless the contemplated transaction closes prior thereto, in
  which case the note will be cancelled. On September 30, 2016, the Company determined this note to no longer be collectible. As
  such, the principal amount of $31,400, the non-refundable deposit amount of $15,000 and accrued interest in the amount of $2,228
  was written off and included in operating expense for the year ended September 30, 2016.
  On August 17,
  2016, the Company entered into a secured promissory note in the amount of $25,000 to advance funds to the sellers of assets in
  regards to the Asset Purchase Agreement referenced in Note 1. This note has an interest rate of 8% per annum, with principal and
  unpaid and accrued interest due on February 17, 2017. On January 29, 2017, the note was deemed uncollectible, the principal amount
  of $25,000 and accrued interest in the amount of $904 was written off and included in operating expense for the nine months ended
  June 30, 2017. As of June 30, 2017, the total outstanding under this note including accrued interest is $-0-.
  NOTE 5 -
  INVESTMENT
  On November 1, 2016,
  pursuant to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the GandTex Assets the Company
  formed two subsidiaries in the state of Nevada, NuLife BioMed, Inc., and NuLife Technologies, Inc. GandTex is a biomedical company
  focused on advancing human organ transplant technology and medical research. The assets being transferred consist of certain proprietary
  patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs, as well as
  management of, and historical data for, animal trials conducted by GandTex.
  On January 29, 2017,
  the Company announced the completion of an Asset Purchase Agreement to acquire the assets (the "Asset Purchase") of
  GandTex, LLC, a Texas limited liability company ("GandTex"). GandTex was the owner of certain patents and licensed
  rights related to biomedical company focused on advancing human organ transplant technology and medical research. The assets consisted
  of certain proprietary patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs,
  as well as management of, and historical data for, animal trials (the "Animal Trials") conducted by a third-party operating
  using the GandTex Assets. Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals, the Company
  agreed to provide additional funding for the Trials in the aggregate amount of $300,000. In exchange for the Assets, the Company
  issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock. GandTex is owned and controlled by a single individual
  Managing Member who beneficially owns 70% of GandTex. The Asset Purchase was approved by a majority of the Company's disinterested
  directors.
  The fair
  value of the preferred stock amounted $2,500,000 is being treated as an expense instead of investment because it is deemed as Stock
  Based Compensation, not an Investment.
  NOTE 6 - CONSULTING AGREEMENT
  On
  April 1, 2015, the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement,
  the Company will pay the consultant a monthly fee of $8,500 on the first day of each month with the payment deferred until the
  Company closes financing in the amount of $3 million or greater. Additionally, the Company was required to issue the consultant
  200,000 shares of common stock on October 1, 2015. During the nine months ended June 30, 2017 and 2016, the Company recorded stock
  based compensation expense in the amount of $-0- and $30,500 associated with the vesting of the common stock, respectively.
  13
  Table of Contents
  On February 28,
  2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.("Global"), a Company owned
  by the Company's President Fred G. Luke ("the "Global Agreement"), pursuant to which the Company retained
  Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve as the Company's
  President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing of the Company's
  its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received an aggregate of 55,000
  shares of restricted Series A Convertible Preferred Stock.
  NOTE 7 – NOTES PAYABLE
  As of June 30,
  2017, the Company had one note payable issued and outstanding to third party lenders with a total principle of $25,000 and accrued
  interest of $14,400. The note was due on June 30, 2015, has an interest rate of 12%. This note remains unpaid. The note is in default
  as of June 30, 2017.
  As of June 30,
  2017, the Company had three notes payable issued and outstanding with a former director with a total principle of $74,500 and accrued
  interest of $10,611. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
  10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
  contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The former director for all three notes
  is East West Secured Developments, LLC, an Arizona Limited Liability Company ("EWSD") of which Mr. Brian Loiselle,
  a former director of and consultant to the Company, was a managing member. On June 30, 2016, the Company entered into Amendment
  #1 to these three notes to extend the due date to the earlier of one week after the closing of a certain contemplated farm property
  acquisition or October 31, 2016. The three notes are currently in default. However, the default interest demand of 18% per month
  by Mr. Loiselle is being disputed by the Company due to the lack of provision for default interest in the notes. The three notes
  have been reclassified to non-related party debt. See also Note 11.
  NOTE 8 – CONVERTIBLE NOTES
  Convertible notes consist of the following:
  June 30, 2017
  (Unaudited)
  September 30,
  2016
  Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due December 2017.
  $
  50,025
  $
  50,025
  Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due August 2019.
  50,000
  50,000
  Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due October 2019.
  50,000
  —
  Convertible note payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due November 2019.
  30,000
  —
  Convertible notes payable, annual interest rate of 8%, convertible into common stock at $0.11 per share and due December 2019.
  605,000
  —
  Convertible note payable, annual interest rate of 12%, convertible into      common stock at a variable rate per share and due June 2018
  78,000
  —
  Unamortized debt discount
  (129,752
  )
  (91,480
  )
  Unamortized debt discount due to beneficial conversion feature
  (516,100
  )
  -)
  217,173
  8,545
  Less current portion
  33,067
  -0-
  Convertible debt, net of current portion and debt discount
  $
  184,106
  $
  8,545
  On September 2,
  2016, the Company amended and restated that certain outstanding promissory note of the Company, dated July 3, 2015, in the principal
  amount of $50,025. The replacement convertible promissory note matures on December 31, 2017 and bears interest at the rate of 8%
  per annum, and the principal and interest due thereunder may be prepaid at any time. The note, together with all interest as accrued,
  is convertible into shares of the Company's common stock at 50% of the trailing average highest closing bid price of the
  Company's common stock on the date of conversion. As of June 30, 2017, the note balance and accrued interest is $50,025 and
  $8,026, respectively.
  14
  Table of Contents
  On August 1, 2016,
  the Company entered into those four (4) Note Purchase Agreements (collectively, the "Purchase Agreements") in connection
  with the issuance of certain convertible promissory notes, dated August 1, 2016 (collectively, the "Purchase Notes")
  in the aggregate principal amount of $50,000. All of the Purchase Notes are due in 36 months. The Purchase Notes bear interest
  at the rate of 8% compounded monthly. The Purchase Notes, together with all interest as accrued, is convertible into shares of
  the Company's common stock at 50% of the trailing average highest closing bid price of the Company's common stock on
  the date of conversion. Due to the beneficial conversion feature of these notes, the Company recorded $50,000 of debt discount
  as a contra liability and amortized $15,205 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the
  Purchase Notes balance and accrued interest is $50,000 and $3,649, respectively.
  During the nine
  months ended June 30, 2017, the Company entered into certain Note Purchase Agreements (collectively the "Purchase Agreements")
  in connection with the issuance of certain convertible promissory notes, in the aggregate principal amount of $685,000. The Purchase
  Notes are due in 36 months. The Purchase Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together
  with all interest as accrued, are each convertible into shares of the Company's common stock at a conversion price of Eleven
  cents ($0.11) per share. Due to the beneficial conversion feature of these notes, the Company recorded $635,545 of debt discount
  as a contra liability and amortized $119,446 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the
  note balances and accrued interest are $685,000 and $31,506, respectively.
  On June 26, 2017,
  the Company entered into a Securities Purchase Agreement ("SAP") in connection with the issuance of a convertible promissory
  note ("Note") in the aggregate principal amount of $78,000. The Note matures on June 30, 2018 (the "Maturity
  Date"), and bears interest at the rate of 12% per annum. After 180 days, the Note may not be prepaid. Any amount of principal
  or interest on this Note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from
  the due date. The Note, together with all interest as accrued, is convertible into shares of the Company's common stock at
  a 35% discount to the lowest trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion
  Date. Due to the beneficial conversion feature of this note, the Company recorded $78,000 of debt discount as a contra liability
  and amortized $846 of the discount during the nine months ended June 30, 2017. As of June 30, 2017, the note balance and accrued
  interest is $78,000 and $103, respectively.
  NOTE 9 – DERIVATIVE LIABILITY
  During August 2016,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $50,025. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company's
  common stock at 50% of the trailing average highest closing bid price of the Company's common stock on the date of conversion.
  The Note accrues interest at a rate of 8% per annum and matures on December 31, 2017.
  During August 2016,
  the Company entered into Loan Agreements with investors pursuant to which the Company issued convertible promissory notes in the
  principal amount of $50,000. The Notes are convertible into shares of common stock at an initial conversion price subject to adjustment
  as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company's common
  stock at 50% of the trailing average highest closing bid price of the Company's common stock on the date of conversion. The
  Notes accrue interest at a rate of 10% per annum and mature on August 1, 2019.
  During June 2017,
  the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
  the principal amount of $78,000. The Note is convertible into shares of common stock at an initial conversion price subject to
  adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company's
  common stock at 65% of the trailing average highest closing bid price of the Company's common stock on the date of conversion.
  The Note accrues interest at a rate of 12% per annum and matures on June 30, 2018.
  Due to the variable
  conversion price associated with these convertible promissory notes, the Company has determined that the conversion feature is
  considered a derivative liability. The accounting treatment of derivative financial instruments requires that the Company record
  the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of
  each subsequent balance sheet date.
  15
  Table of Contents
  The initial fair
  value of the embedded debt derivative of $298,140 was allocated as a debt discount in the amount of $175,025 and excess $123,115
  was charged to interest expenses, loss on derivative. The fair value of the described embedded derivative was determined using
  the Black-Scholes Model with the following assumptions:
  June 26, 2017
  March 31, 2017
  September 30, 2016
  (1) dividend yield of
  0%;
  0%;
  0%;
  (2) expected volatility of
  250%,
  311%,
  243% - 413%,
  (3) risk-free interest rate of
  1.20% - 1.24%,
  1.47%,
  0.50% - 0.88%,
  (4) expected life of
  1 year
  1-3 years
  1-3 years
  (5) fair value of the Company's common stock of
  $0.67 per share.
  $0.60per share.
  $0.11 per share.
  During the nine
  months ended June 30, 2017 and 2016, the Company recorded the loss in fair value of derivative and derivative expense in the amount
  of $39,579 and $-0-, respectively.
  For the nine months
  ended June 30, 2017, $39,727 and $-0-, were expensed in the statement of operation as amortization of debt discount related to
  above notes and shown as interest expenses, respectively.
  The following table
  represents the Company's derivative liability activity for the period ended:
  Balance at September 30, 2016
  $
  169,221
  Initial measurement at issuance date of the notes
  103,520
  Derivative expense
  -
  Change in fair value of derivative at period end
  11,059
  Balance June 30, 2017
  $
  283,800
  NOTE 10 – SHARE CAPITAL
  The Company is
  authorized to issue 475,000,000 shares of common stock and 25,000,000 shares of preferred stock.
  On April 1, 2015,
  the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company granted
  200,000 shares of restricted common stock to the investor relations firm which fully vested on October 1, 2015. The final issuance
  resulted in 600,000 shares of restricted common stock due to the three-for-one forward stock split. On the date of the consulting
  agreement was entered into, April 1, 2015, the shares were valued at $1.00 per share which was the unadjusted share price prior
  to three-for-one forward stock split. The subject shares of common stock were issued on March 29, 2016. During the year ended September
  30, 2015, the Company recorded share based compensation expense in the amount of $200,000 associated with the vesting of the common
  stock granted. On March 31, 2016, the Company and the investor relations firm entered into Amendment #1 to the consulting agreement
  to suspend the monthly fee indefinitely until such time as the Company requests that the services resume.
  On April 21, 2015,
  the Board of Directors of the Company approved a three-for-one forward stock split of the Company's common stock. Accordingly,
  shareholders owning shares of the Company's common stock will receive two additional shares of the Company for each share they
  own. The Company had 10,128,600 shares issued and outstanding prior to the forward stock split. At September 30, 2016 and September
  30,2015 the Company has 31,085,800 shares and 30,385,800 shares, respectively, of common stock issued and outstanding. The Company
  received notification from the Financial Industry Regulatory Authority (FINRA) on May 7, 2015, that it could proceed with the three-for-one
  forward stock split. Additional funds were reallocated from Additional Paid in Capital to the Common Stock account in an amount
  equal to the additional par value represented by the additional shares issued under the stock split. All share information presented
  in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the increased number of shares
  resulting from this transaction.
  16
  Table of Contents
  On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vested over a six-month period; accordingly, during the six months ended March 31, 2016, the Company recorded stock based compensation
  expense in the amount of $61,000 associated with vesting of the common stock granted. The subject shares of common stock were issued
  on March 29, 2016. During the year ended September 30, 2016, the Company recorded stock based compensation expense in the amount
  of $43,098, associated with vesting of common stock granted.
  On October 31, 2016,
  the Company amended and restated its Articles of Incorporation. The purpose of the amendment and restatement of the Articles of
  Incorporation was to:
  (i)
  Change the Company's name from "SmooFi, Inc." to "NuLife Sciences, Inc."
  (ii)
  Symbol change from "SMFI" to "NULF";
  (iii)
  Increase the number of authorized shares of Preferred Stock to 25,000,000;
  (iv)
  Increase the number of authorized shares of Common Stock to 475,000,000;
  (v)
  Define, with respect to the Preferred Stock, the manner in which the Board may define the powers, preferences, rights, and restrictions thereof.
  Concurrent with
  the Company's increase of its authorized common and preferred stock, the Company requested and received from, the Financial
  Industry Regulatory Authority, approval for a name change from Smoofi, Inc. to NuLife Sciences, Inc., and a symbol change from
  "SMFI" to "NULF".
  Also on October
  31, 2016, the Company adopted a 2016 Non-Qualified Incentive Stock Compensation Plan (the "Compensation Plan"), and
  reserved 7,000,000 shares for issuance from the Compensation Plan. As of the date of this report no shares have been issued from
  the Compensation Plan.
  On November 1, 2016,
  the Company amended and restated its Bylaws, providing for a change in the Company's name from "SmooFi, Inc."
  to "NuLife Science, Inc."
  On November 1, 2016,
  the Board approved the Certificates of Designation to create and provide for the rights, preferences, and privileges of 2,000,000
  shares of the Company's Series A Convertible Preferred Stock and 10,000,000 shares of the Company's Series B Convertible
  Preferred Stock.
  Description of Preferred Stock:
  Series A Preferred
  Stock
  •
  As authorized in the Company's Amended and Restated Articles
  of Incorporation, the Company has 2,000,000 shares of Series A Preferred Stock authorized with the following characteristics:
  o
  Holders of the Series A Stock shall be entitled to receive dividends
  or other distributions with the holders of the Common Stock on an "as converted" basis when, as, and if declared by
  the Directors of the
  Corporation.
  o
  Holders of shares of Series A Preferred Stock, upon Board of Directors approval, may convert
  at any time following the issuance upon sixty-one (61) day written notice to the Corporation. Each share of Series A Preferred
  Stock shall be convertible into such number of fully paid and non-assessable shares of Common Stock as is determined by multiplying
  the number of issued and outstanding shares of the Corporation's Common Stock together with all other derivative securities,
  including securities convertible into or
  exchangeable for Common Stock,
  whether or not then convertible or exchangeable (b) subscriptions, rights, options and warrants to purchase shares of Common Stock,
  whether or not then exercisable, but entitled to vote on matters submitted to the Shareholders
  17
  Table of Contents
  (collectively, "Derivative
  Securities"), issued by the Corporation and outstanding as of the Date of Conversion, by .000001, then multiplying that number
  of shares of Series A Stock to be converted.
  o
  In case of any consolidation or merger of the Corporation, the Corporation
  shall mail to each holder of Series A Stock at least thirty (30) days prior to
  the
  consummation of such event, a notice thereof and each such holder shall have the option to either (i) convert such holder's
  shares of Series A Shares into shares of Common Stock pursuant to this paragraph and thereafter receive the number of shares of
  Common Stock or other securities or property, or cash, as the case may be, to which a holder of the number of shares of Common
  Stock of the Corporation deliverable upon conversion of such Series A Stock would have been entitled upon conversion immediately
  preceding such consolidation, merger or conveyance, or (ii) exercise such holder's rights pursuant to Section 8.1(a) hereof;
  provided however that the Series A Stock shall not be subject to or affected as to the number of Conversion Shares or the redemption
  or liquidation price by reason of any reverse stock split affected prior or as a result of any reorganization.
  o
  In the event of a liquidation, the holders of shares of the Series
  A Stock shall be entitled to receive, prior to the holders of the other series of Preferred Stock and prior and in preference to
  any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the Corporation
  by reason of their ownership of such stock, an amount equal to Five Dollar ($5.00) per share with respect to each share of Series
  B Stock owned as of the date of Liquidation, plus all declared but unpaid dividends with respect to such shares, and thereafter
  they shall share in the net Liquidation proceeds on an "as converted basis" on the same basis as the holders of the
  Common Stock.
  o
  The holders of each share of Series A Stock shall have that number
  of votes as determined by multiplying the number of issued and outstanding shares of the Corporation's Common Stock together
  with all other derivative securities issued by the Corporation and outstanding as of the Date of Conversion, whether or not then
  convertible or exchangeable, entitled to vote on matters submitted to the Shareholders, by .000001, then multiplying that number
  of shares of Series A Stock to be converted.
  o
  The Corporation shall have the option to redeem all of the outstanding
  shares of Series A Stock at any time on an "all or nothing" basis, unless otherwise mutually agreed in writing between
  the Corporation and the holders of shares of Series A Stock holding at least 51% of such A Stock, beginning ten (10) business days
  following notice by the Corporation, at a redemption price the higher of (a)Five Dollar ($5.00) per share, or (b) Fifty percent
  (50%) of the trailing average highest closing Bid price of the Corporation's Common Stock as published at www.OTCMarkets.com
  or the Corporation's primary listing exchange on the date of Notice of redemption, unless otherwise modified by mutual written
  consent between the Corporation and the Holders of the Series A Stock (the "Conversion Price"). Redemption payments shall
  only be made in cash within sixty (60) days of notice by the Corporation to redeem.
  o
  The shares of Series A Stock acquired by the Corporation by reason of conversion or otherwise
  can be reissued, but only as an amended class, not as shares of Series A Stock.
  Series B Preferred
  Stock
  In conjunction with the Asset Acquisition
  with GandTex, as authorized in the Company's Amended and Restated Articles of Incorporation, the Company initially filed
  a Certificate of Designation creating a series A Preferred Stock consisting of 10,000,000 shares of Series B Preferred Stock with
  the following characteristics:
  o
  Holders of shares of Series B Preferred Stock, upon Board of Directors approval, may convert
  at any time following the issuance upon sixty-one (61) day written notice to the Corporation. Each share of Series B Preferred
  Stock shall be convertible into such number of fully paid and non-assessable shares of Common Stock as is determined by
  18
  Table of Contents
  percentage of the net income which
  is achieved by SMFI and its subsidiaries (the "Actual Net Income ") versus the projections (detailed in Exhibit A to
  this Certificate of Designation of Series B Convertible Preferred) provided by GandTex (the "Projected Net Income")
  at any time during the two (2) year term following the Closing of the Purchase Agreement. This calculation will be made by dividing
  the Actual Net Income achieved by SMFI and its subsidiaries related to the development and commercialization of the GandTex Assets
  by the Projected Net Income (attached hereto as Exhibit A to this Certificate of Designation of the Series B Convertible Preferred
  Stock) on the Notice to Convert (as defined below), then dividing that product into 1 share of Series B Stock. The formula of this
  calculation is:
  1 Share of Series B Stock
  Number of Shares
  = of Common
  Upon Conversion of
  (Actual Net Income)
  1 Share of Series B
  (Projected Net Income)
  Stock
  o
  Holders of the Series B Stock shall be entitled to receive dividends
  or other distributions with the holders of the Common Stock on an "as converted" basis when, as, and if declared by
  the Directors of the Corporation.
  o
  In case of any consolidation or merger of the Corporation, the Corporation
  shall mail to each holder of Series B Stock at least thirty (30) days prior to the consummation of such event, a notice thereof
  and each such holder shall have the option to either (i) convert such holder's shares of Series B Shares into shares of Common
  Stock pursuant to this Paragraph 3 and thereafter receive the number of shares of Common Stock or other securities or property,
  or cash, as the case may be, to which a holder of the number of shares of Common Stock of the Corporation deliverable upon conversion
  of such Series B Stock would have been entitled upon conversion immediately preceding such consolidation, merger or conveyance,
  or (ii) exercise such holder's rights pursuant to Section 9.1(a) hereof.
  o
  In the event of a liquidation, the holders of shares of the Series
  B Stock shall be entitled to receive, second to the holders of Series A Preferred Stock, but prior to the holders of the other
  series of Preferred Stock and prior and in preference to any distribution of the assets or surplus funds of the Corporation to
  the holders of any other shares of stock of the Corporation by reason of their ownership of such stock, an amount equal to One
  Dollar ($1.00) per share with respect to each share of Series B Stock owned as of the date of Liquidation, plus all declared but
  unpaid dividends with respect to such shares, and thereafter they shall share in the net Liquidation proceeds on an "as converted
  basis" on the same basis with the holders of the Common Stock.
  o
  Shares of Series B Preferred Stock shall have no voting rights in
  respect of matters submitted for a vote of the holders of Common Stock;
  o
  the Corporation shall have the option to redeem all of the outstanding
  shares of Series B Stock at any time on an "all or nothing" basis, unless otherwise mutually agreed in writing between
  the Corporation and the holders of shares of Series B Stock holding at least 51% of such A Stock, beginning ten (10) business days
  following notice by the Corporation, at a redemption price of One Dollar ($1.00) per share. Redemption payments shall only be made
  in cash within sixty (60) days of notice by the Corporation to redeem.
  o
  The shares of Series B Stock acquired by the Corporation
                                                                                                                                                    by
                                                                                                                                                    reason of conversion or otherwise can be reissued, but only as an amended class, not as shares of Series B Stock.
  19
  Table of Contents
  As
  described in Footnote 5 above, pursuant to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board
  approved the issuance of 10,000,000 shares of the Company's Series B Convertible Preferred Stock to GandTex. The shares were
  released to GandTex concurrent with the closing on January 29, 2017.
  On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the "Conversion Agreement") in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC("MZ") by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the "Released Debt") together with a release by MZ in favor
  of the Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of
  fees or costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the
  Conversion Agreement, and in exchange for the release, the Company issued to MZ an aggregate of 55,000 shares of restricted Series
  A Convertible Preferred Stock.
  Valuation of Series A and Series
  B Preferred Stock.
  The
  initial Certificate of
  Desig
  nation for both the Series A Stock and the Series B Stock had very similar characteristics and
  the same requirement that any conversion must be approved by the Company's Board of Directors limits the ability of the holders
  to convert both the Series A Stock and the Series B Stock. In part, each of the two Certificates of Designation initially had the
  following requirements,"
  3.1
  Conversion.
  Upon Board of Directors approval, each share of Series A [B] Preferred
  Stock shall be convertible, subject to notice requirements of paragraph 3.2, at any time following the issuance of such shares
  Series A [B] Stock, into such number of fully paid and non-assessable shares of Common Stock…".
  This limiting
  ability to convert the Series A [B] Stock significantly reduces their Fair Market Value. However, by utilizing the most readily
  available information and analogy, in the case of both the Series A Stock and Series B
  Stock
  this would be the issuance of the Series A Stock to MZHCI, a non-affiliate, for the extinguishment of debt of $13,750 for 55,000
  shares of Series A Stock, or $.25/share. By analogy, the 55.000 shares of Series A stock issued to Global Business Strategies Inc.
  ("GBSI") were also valued at $.25 per share: The Series B Stock issued to GandTex, again by analogy, was also valued
  at $.25 per share.
  Utilizing this model,
  the Series A shares issued to MZHCI and GBSI were valued in the aggregate at $13,750 each, and the Series B shares issued to GandTex
  were initially valued at $2,500,000 and its being treated as an expense.
  Further, as a result
  of the delayed onset of revenue and the regulatory approval timelines, the original estimates as to the timelines for the Animal
  Trials, making it impact able for the Company to proceed, or to achieve the projected benchmarks as to the completion date of the
  Animal Trials and obtaining approval from the requisite regulatory bodies as originally represented at Closing. As a result, the
  Company agreed to amend certain aspects of the GandTex Asset Acquisition Agreement, including the conversion formula of the Series
  B Convertible Preferred Stock issued to GandTex. The Amended and Restated Certificate of Designation creating a Series B Preferred
  Stock is to be amended to change the terms of conversion, and eliminated the requirement that GandTex, or any assignee of any of
  the Series B Stock, obtain approval that any conversion must be approved by the Company's Board of Directors, with all other
  of the original terms remaining unchanged. The Amended and Restated Certificate of Designation for the Series B Stock has not yet
  been filed with the state of Nevada, but will be shortly after we receive fully the executed Amendment Documents -see NOTE 13 -
  SUBSEQUENT EVENTS. Pursuant to the proposed amended conversion features, the 10,000,000 shares of Series B Preferred Stock can
  be converted as follows:
  .
  "3.0	Conversion
  into Common Stock.
  3.1
  Conversion.
  One million shares of Series B Prefer
  r
  ed Stock shall be
  convertible into two million shares (l-for-2 ratio) of common stock of the Co
  r
  poration
  ,
  subject to notice requ
  i
  rements
  of pa
  r
  agraph 3.2
  ,
  one
  year from the date the holder receives its shares of Series B Preferred Stock
  ,
  into
  such number of fully paid and non-assessable shares o
  f
  Common
  Stock.
  N
  i
  ne
  million shares of Series B P
  r
  eferred Stock shall be convertible
  into twenty-seven million shares (l-for-3 ratio) of Common Stock
  ,
  subject
  to notice requirements of paragraph 3.2
  ,
  at
  s
  uch
  time onl
  y
  when the Corporation has annual gross revenues
  of $60
  ,
  000,000 deriv
  i
  ng
  from the Gandy
  /
  Gandtex patents or processes, into
  s
  uch
  number of fully paid and non-assessable shares of Common Stock."
  20
  Table of Contents
  Stock Options
  Pursuant to the
  Employment Agreement with Mr. Hollister, Mr. Hollister is to be granted option to purchase up to 1,500,000 shares of the Company's
  Common Stock. However, as of the date of this report the option price of the underlying shares has not been calculated, and the
  Option Agreement has not been executed – see Footnote 13. Subsequent Events.
  On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company's President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement (the "Option Agreement") which was Fourteen cents ($0.14)
  per share and subject to certain adjustments on November 15, 2016. The options vested immediately.
  Stock option transactions for the
  nine months ended June 30, 2017 are summarized as follows:
  Shares
  Weighted Average
  Exercise
  Price
  Weighted Average Remaining
  Term
  Aggregate
  Intrinsic Value
  Outstanding, September 30, 2016
  -
  $
  -
  -
  Granted
  1,500,000
  0.14
  3.0
  186,904
  Exercised
  -
  -
  Expired
  -
  -
  Outstanding, June 30, 2017
  1,500,000
  0.14
  2.4
  Exercisable, June 30, 2017
  1,500,000
  $
  .0.14
  2.4
  The initial fair
  value of the option was $186,904 charged to operating expense during the nine months ended June 30, 2017. The fair value of the
  option was determined using the Black-Scholes Model with the following assumptions:
  (1) dividend yield of
  0%;
  (2) expected volatility of
  236%,
  (3) risk-free interest rate of
  1.28%,
  (4) expected life of
  3 years, and
  (5) fair value of the Company's common stock of
  $0.13 per share.
  The fair value
  of options exercised in the three and nine months ended June 30, 2017 and 2016 was $0 and $0, and $0 and $0, respectively.
  The Company
  recorded $0 and $43,098, and $2,700,654 and $43,098 of stock compensation expense in the statements of operations for the three
  and nine months ended June 30, 2017 and 2016, respectively, related to non-vested share-based compensation arrangements granted
  under existing stock option plans.
  As of June
  30, 2017, there was $0 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted
  under existing stock option plans.
  NOTE 11 - RELATED PARTY TRANSACTIONS
  In
  April of 2015 Mr. Brian Loiselle, a former director of the Company, agreed to transfer his ownership interest in a cannabis farm
  and related equipment known as the "Tamarack Project", which was the subject of a certain Letter of Intent to which the
  Company was a party. In addition, it was proposed that Mr. Cahill sell all of his 21,750,000 shares of the Company to Blue River
  Equity LLC, an Arizona Limited Liability Company ("Blue River"), a company controlled by Mr. Loiselle. The transfer
  of the Tamarack Project, and other projects which Mr. Loiselle offered in substitution for the Tamarack Project were never acquired
  by Mr. Loiselle and, therefore could not be transferred to the Company, resulting in a breach of the representations by Mr. Loiselle,
  for himself and on behalf of Blue River, and the failure of Mr. Loiselle and/or Blue River to cause any property to be transferred
  into
  21
  Table of Contents
  the
  Company. Consequently, as a result of the breach and failure to deliver the primary consideration for the shares held by Mr. Cahill.
  Mr. Cahill never transferred the subject shares thereby voiding the agreement between himself and Blue River, and retained Beneficial
  Ownership of the subject shares as evidenced by Mr. Cahills filing of a Beneficial Ownership Report on Form SC-13G on October 4,
  2016.
  In
  addition, Mr. Loiselle induced the Company to make a non-refundable payment of $50,000 in connection with his attempt to purchase
  a replacement cannabis farm and property, the "Stroud Farm", which never closed and the $50,000 was written off in
  the year ended September 30, 2015. After giving Mr. Loiselle several extensions of time to perform on his proposed multi-part transaction,
  we severed relations with Mr. Loiselle in August 2016. As of September 30, 2016, $53,200 was due to Mr. Loiselle and included as
  Due to Related Party which is in dispute as described below.
  Effective January
  1, 2016, in recognition of the absence of employment and consulting agreements and the time commitment to the Company on the part
  Mr. Sean Clarke, the Company's Chief Financial Officer and sole director, and Brian Loiselle, a former member of the Board of Directors,
  respectively, the Board of Directors on March 31, 2016 approved monthly compensation in the amount of $10,000 to be paid to Mr.
  Sean Clarke and Brian Loiselle, to be deferred and accrued and only paid following the Closing of the purchase of the Stroud Farm
  and at such time as the Company has the necessary financial resources. Effective April 1, 2016, such monthly compensation was revised
  from $10,000 to $5,000, but the Board of Directors reaffirmed that such payment was to be deferred and accrued, and only paid following
  the Closing of the purchase of the Stroud Farm and at such time as the Company has the necessary financial resources At September
  30, 2016, $53,200 has been accrued and is included in accrued expenses
  .
  However, the Company severed the relationship
  with Mr. Loiselle in August 2016 following the failure of close on the purchase the Stroud Farm and, therefore, the Company is
  disputing the obligation for payment of these accrued consulting fees.
  As
  of June 30, 2017, the Company had three notes payable issued and outstanding with an entity controlled by Mr. Loiselle with a
  total principle of $74,500 and accrued interest of $10,611. The three notes, in the amount of $47,000, $15,000 and $12,500,
  were issued on January 14, 2016. February 10, 2016 and February 29, 2016, respectively. The three notes are due on the
  earlier of one week after the closing of a certain contemplated farm property acquisition or July 31, 2016, and have an
  interest rate of 10%. The related party for all three notes is EastWest Secured Developments, LLC; an Arizona Limited
  Liability Company ("EWSD") of which Mr. Brian Loiselle, a director of and consultant to the Company, is a
  managing member. On June 30, 2016, the Company entered into Amendment #1 to these three notes to extend the due date of the
  three notes is October 31, 2016. As of March 31, 2017, the Company owed EWSD $53,200 of accrued and unpaid services which is
  reported as accrued expenses. Mr. Loiselle's services terminated in July 2016 ending his affiliation with the Company
  and therefore neither he nor EWSD were considered a Related Party at June 30, 2017.
  On
  April 22, 2015, the Company and Newport Board Group entered into an Advisory Services Agreement whereby Mr. Donahue would
  serve as the Company's Chief Operating Officer. The term of the initial agreement was for 60 days. The Board of Directors approved
  by resolution to extend the Agreement with the Newport Board Group on June 9, 2015, but no definitive agreement was signed and
  no set termination date was set; however, the resolutions provided for either party to terminate the extension at any time with
  30 days' written notice. The monthly fee under the original agreement was $4,000 to be paid monthly for Mr. Donahue to serve as
  the Chief Operations Officer and was negotiated and connected to the original proposed transfer of the Tamarack Project to the
  Company by Mr. Loiselle.
  During
  the nine months ended June 30, 2017, the Company paid $-0- to Newport Board Group, with an additional $59,633 of monthly fees deferred
  and included as accrued expenses at June 30, 2017. During the nine months ended June 30, 2016, the Company paid $-0- to Newport
  Board Group, with an additional $21,500 of monthly fees deferred and included as Due to Related Party at September 30, 2016. The
  Company terminated the extension in September 2016, effective October 15, 2016. The Company has continued to defer and accrue all
  additional fees through October 15, 2016. On August 7, 2015, the Company granted 100,000 shares of restricted common stock to Mr.
  John Donahue, the Company's former Chief Operations Officer. As of June 30, 2017, the Company owed Newport Board Group $59,633
  of accrued and unpaid services which is reported as accrued expenses, but Mr. Donahue's services terminated in September
  2016 ending his affiliation with the Company and therefore was not considered a Related Party at June 30, 2017.
  As
  of June 30, 2017, the Company owed Mr. Clarke and Mr. Luke $52,500 and $-0-, respectively, of accrued and unpaid compensation.
  These amounts are included as Due to Related Party at June 30, 2017.
  22
  Table of Contents
  On September 16
  2016 we asked Mr. John Hollister to join our management team as our Chief Executive Officer. Due to the financial constraints of
  the Company Mr. Hollister did not accept the offer. However, in October 2016 Mr. Hollister agreed to serve as a consultant, then
  as our interim our Chief Executive Officer, pending the completion of the sale the Purchase Notes. A definitive agreement was agreed
  upon and executed between the Company and Mr. Hollister on May 15, 2017, and contained the agreement for the Company to grant Mr.
  Hollister Options to purchase up to 1,500,000 shares of the Company's Common Stock, vesting upon certain events. The Option
  Agreement has not yet been executed. A copy of the Employment Agreement with Mr. Hollister was filed on Form 8-K on May 17, 2017-
  On November 15,
  2016, the Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company's President, at an
  exercise price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of
  such shares on the date of execution of the Option Agreement (the "Option Agreement") which was Fourteen cents ($0.14)
  per share and subject to certain adjustments on November 15, 2016. The options are valued at $186,904 and recorded as expense
  during the nine months ended June 30, 2017.
  On May 15,2017 the
  Company entered into an Employment Agreement with Mr. John Hollister to serve as the CEO of the Company. In addition to his role
  as CEO, Mr. Hollister will serve as the President of NuLife BioMed and be in charge of all aspects of the Animal Trials, review
  of the data submitted to the Food and Drug Association ("FDA"), and the Clinical Trials, subject to the approval by
  the FDA of our Animal Trial results and conclusions.
  In
  March, 2017, we retained Dr. Youxue Wang MD, PhD to serve as the Director of Research for NuLife Biomed Inc. Doctor Wang has been
  working for several months for us in the development of the pre-clinical pig study protocol, which was recently up-loaded to the
  review board at Florida International University ("FIU") for approval. We currently finalized the terms of an Advisory
  Agreement with South Broward Hospital District d/b/a Memorial Healthcare System
  ("
  Memorial"),
  the current employer of Doctors Arenas and Hranjec, both transplant surgeons, to perform the actual organ removal and replacement
  during the Animal Trials. Doctors Wang, Arenas, and Hranjec have recently received medical clearance from FIU to conduct the surgeries.
  NOTE 12 –
  LEASE AGREEMENT
  During May 2017,
  the executed a 5-year lease for a laboratory at NOVA Southeastern University at which the Company will be utilizing the NuLife
  Technique to process organs, as well as conducting bench research to better characterize and assess the impact of the technique.
  The lease calls for monthly payments of $2,582, which includes the initial base rent of $1,925 along with applicable taxes and
  shared operating expenses. The lease required a security deposit in the amount of $4,871 and requires a 4% increase in base rent
  annually. Rent expense for the nine months ended June 30, 2017 and 2016 was $2,742 and $-0-, respectively.
  Future minimum lease
  payments are as follows for the years ending:
  September 30, 2017 (remaining three months)
  $
  5,775
  September 30, 2018
  23,408
  September 30, 2019
  24,344
  September 30, 2020
  25,318
  September 30, 2021
  26,331
  September 30, 2022
  18,016
  $
  123,192
  NOTE 13 -
  CONTINGENCY
  As
  of June 30, 2017, as described in Note 11, the Company has accrued $53,200 in Due to Related party - Mr. Loiselle
  ,
  note
  payable of $74,500 and accrued interest of $10,611 due EWSD. At June 30,2017 the Company owed EWSD the aggregated amount of
  $138,311, which is past due and has been in default since October 31, 2016. On top of the amount accrued by the Company, Mr. Loiselle
  had demanded for a penalty fee of $101,235, which is approximately 18% monthly default rate on the amount past due. We believe
  the penalty fee imposed is invalid and are currently in dispute with Mr. Loiselle.
  23
  Table of Contents
  NOTE 14
  - SUBSEQUENT EVENTS
  Aa
  result of third-party delays related to the Company (a) gaining approval for its "Protocal" for the Animal Trials,
  (b) finalizing the terms of the Lease for its Lab facilities at NOVA Southeastern University, (c) finalizing the terms of the agreement
  with South Broward Hospital District d/b/a Memorial Healthcare System
  ("
  Memorial"),
  the current employer of the two transplant surgeons who the Company intends to retain to carry out the remaining Animal Trials,
  and (d) other issues out of the control of the Company, the original estimates as to the timelines for the Animal Trials, revenue
  projections , and other representations by GandTex in the original GandTex Asset Acquisition Agreement, made it impact able for
  the Company to rely on the original projected benchmarks as to the completion date of the Animal Trials, obtaining approval from
  the requisite regulatory bodies, or the revenue projections as originally represented by GandTex at Closing. As a result, GandTex
  agreed to amend certain aspects of the Asset Acquisition Agreement, and agreed to provide us with a Lockup Agreement and an Indemnity
  Agreement. In consideration for these added agreements (the "Amendment Documents"), we agreed to amend the conversion
  formula of the Series B Convertible Preferred Stock issued to GandTex and take the GandTex Assets subject to a Royalty Agreement.
  The Amendment Documents will be included as Exhibits in an Form 8-K filed by the Company concurrently with the countersignature
  of the documents and the filing of the Amended and Restated Certificate of Designation of the Series B Convertible Preferred Stock.
  We finally resolved
  the majority of the causes of delays and resumed Animal Trials during the first week in August 2017.
  24
  Table of Contents
  ITEM 2. MANAGEMENT'S DISCUSSION AND
  ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  The information contained in this
  Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended September 30, 2016
  and presumes that readers have access to, and will have read, the "Management's Discussion and Analysis of Financial Condition
  and Results of Operations" and other information contained in such Form 10-K. The following discussion and analysis also should
  be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.
  Except for historical information,
  the matters discussed in this section are forward looking statements that involve risks and uncertainties and are based upon judgments
  concerning various factors that are beyond the Company's control. Consequently, and because forward-looking statements are inherently
  subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed
  in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report.
  We strongly encourage investors to carefully read the factors described elsewhere in this report in the section entitled "Risk
  Factors" for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking
  statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q.
  The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere
  in this report.
  Company Overview
  As
  a result of the Company not receiving the working capital promised by certain third parties, development of the two business segments
  described below has been slow, and generated less than expected revenue since its inception on October 15, 2013. However, in August
  2016 we elected to modify our initial business plan to suspend pursuing our online marketing business and the subsequent cannabis
  activities in favor of the acquisition and development of the patents and other rights owned by
  GandTex
  .
  As part of this new direction into the medical and healthcare industry, subsequent to the date of this report – See Subsequent
  Events – we acquired the GandTex License and Patent rights related to a proprietary technique for organ transplants, as discussed
  below.
  Online marketplace
  and community
  The
  Company's initially-defined business strategy is to acquire and/or develop and market software and services that will significantly
  enhance the performance and functionality of the Internet services used by individuals and by small to medium sized businesses.
  The Company's products and services, essentially an online marketplace and community, will use proprietary technology that will
  enable users, both service requestors and service providers, to work collaboratively to obtain substantial improvements in performance,
  reliability and usability. Service requestors (people or companies requesting a service) name their own price, date and time for
  any service. A service requestor can also select qualifying criteria such as number of reviews or review rankings of a service
  provider. The first service provider who can provide that service, on that date, at that time and meets the service ranking requirements
  will get the project
  The
  Company's online marketplace and online community was designed to match up daily job or service requests and fill market demand
  for service requests throughout a particular local community, county or city and will connect local resources with local needs.
  A goal is to create jobs and provide market value for basic services by aggregating these low-cost services within each local market.
  This will maximize value for either the person or company requesting the service and for the person or company providing the service.
  In other words, service providers will get the best possible price for their service and the party requesting the service will
  pay the lowest possible price. Since the acquisition of the organ transplant technology, we have narrowed the focus of our platform
  to the healthcare industry and intend to include a section in our platform dedicated to providing educational information as to
  the various options available to those in need of transplants.
  25
  Table of Contents
  Operations,
  Consulting and Advisory Services in the Organ Transplant segment of the Healthcare Industry
  With
  the acquisition of the GandTex technology the Company intends to move into the Healthcare industry. We intend to modify our online
  marketplace and community to focus on healthcare professionals and those in need of individual at-home and post-operative care,
  together with Hospitals and physicians who need part time or additional personnel due to expansion. With this as one form of entry
  into the Healthcare space we will ultimately transform the company into a biomedical company, initially focused on advancing human
  organ transplant and tissue repair technology, and medical research which could potentially eliminate the need for organ or tissue
  match and anti-rejection drugs.
  The
  GandTex technology was developed through 15 years of committed research. The results of the most recent Animal Trials conducted
  outside the U.S. indicate that this technology may produce dramatic breakthroughs in hematopoietic research and transplant techniques.
  The goal of the research was to address the issues of organ compatibility and the need for anti-rejection drugs in the donor.
  The
  procedure itself, in its simplified format, follows six (6) steps: First the organ is removed, or the donor organ is examined.
  Then the Organ is put through a decellularization processes to isolate the extracellular matrix (ECM) of a tissue from its inhabiting
  cells, leaving an ECM scaffold of the original tissue. Specific cells are then harvested from bone marrow of the intended recipient.
  Following the bone marrow harvest the Particular hematopoietic cells are used in the process as well as a novel procedure involving
  temperature and pressure factors (under vacuum). As a result of the vacuum process, specific cells are released from platelets
  without complete platelet degranulation. The negative pressure created by the vacuum pulls the growth factors out of the platelets
  and into the plasma. Once processed, the cells are reintroduced into the recipient influencing further growth of an already implanted
  and recellularized organ. In addition to eliminating the need for tissue matching between donor and recipient, the NuLife Technique
  may have the potential to limit or eliminate the need for anti-rejection drugs.
  Beginning
  over 3 years ago Pilot Studies were conducted: initially the 1
  st
  surgery was conducted in Ecuador, with 3 additional
  animal surgeries, one in the United States. Each study involved 2-3 animals per surgery, and all but one – unknown to the
  study group and the surgeons involved - had a virus prior to the transplant surgery, and did not pass the post-operative examination.
  In
  the U.S. ~31,000 organ transplants occur every year but there are ~123,000 people on the candidate waiting list for a
  transplant. 22 people die each day in America waiting for transplants that can't take place because of the shortage of
  donated organs, due to failed tissue matches. Additionally, the average costs of the immunosuppressive drugs is approximately
  $17,000 per year (Medicare only covers the first three years): and these drugs can also cause increased infection and cancer
  rates - ultimately destroying the transplanted organ and other organs. Further, even with the immunosuppression medication,
  an individual recipient of an organ with the correct tissue match can still suffer rejection.
  Kidney
  transplants will be the Company's initial target market as most common transplants – about 18,000 in 2015 – are
  Kidney transplants; most Kidney transplants patients spend years on dialysis while waiting; many Kidney transplants never receive
  the actual transplant due to the failure in finding the proper tissue match; and, all current Kidney transplant patients require
  anti-rejection drugs.
  It is our intention, and hope, that the GandTex technology
  will enable us to change the face of organ transplantation as we know it today. This expectation, which has only been conducted
  in animal trials outside the United States to date, resulted in the recipient animals not having to have tissue match and eliminated
  the need for anti-rejection drugs post-surgery.
  What
  this means to the individual in need of an organ transplant, a Kidney for example, is that the individual will no longer have to
  wait, often for years, for a matched organ or have to endure the expensive anti-rejection drugs following the replacement. And,
  for Kidney transplants, if our human trials are successful and he FDA approves the procedure, the recipients will no longer have
  to rely dialysis while waiting for a match, or have a need for dialysis post-transplant. If successful during pre-clinical and
  clinical trials, and approved for public use we intend to brand the technology as the "NuLife Process".
  26
  Table of Contents
  Commercialization
  of the NuLife Process requires successful completion of a series of pre-clinical and clinical trials, as well as the demonstration
  of the reproducibility of the process. The steps include but are not limited to pre-clinical studies, defining the Chemistry, Manufacturing
  and Controls (CMC), documentation and necessary support about the process, and an escalating series of studies (Phase I, II and
  III) helping define the safety and efficacy of this process. These data will be evaluated by the FDA and/or other similar health
  authority. If authorization for marketing is granted, the Company plans to work with the existing Organ Procurement Organization
  (OPO) and major transplant centers to form a network of regional facilities capable of executing the process. In addition, Phase
  IV studies are commonly required for ongoing evaluations of safety and efficacy. In parallel with the development, health economics
  analyses will be conducted, in order to support the ultimate need for reimbursement in the markets it is made available.
  The
  Company will routinely assess options for developing and commercializing the NuLife Process, which could include development or
  marketing partnerships, licensing of alternate potential uses, or collaborations with existing companies in the transplant field.
  Further, the Company intends to vigorously pursue non-dilutive grants to aid in the development process.
  Critical Accounting Policies
  The preparation
  of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States
  of America requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses
  and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined
  a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition
  and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result
  of the need to make estimates of matters that are inherently uncertain. We believe that our estimates and assumptions are reasonable
  under the circumstances; however, actual results may vary from these estimates and assumptions. We have identified in Note 2 -
  "Summary of Accounting Policies" to the Financial Statements contained in this Quarterly Report certain critical accounting
  policies that affect the more significant judgments and estimates used in the preparation of the financial statements
  .
  Going Concern
  Our auditor has
  issued a "going concern" qualification as part of its opinion in the Audit Report for the fiscal year ended September
  30, 2016, and our financial statements as of and for the year then ended include a "going concern" footnote (See Footnote
  3 – Going Concern) disclosing that our ability to continue as a going concern is contingent on us to be able to raise working
  capital to generate revenue by completing and launching our online marketplace and community portal and implementing the new business
  strategy of developing the NuLife Process.
  Results of Operation
  Three Months Ended June 30, 2017
  and 2016
  Revenue
  Revenue was $0
  for the three months ended June 30, 2017 and 2016.
  Cost of Sales
  Cost of sales
  was $0 for the three months ended June 30, 2017 and 2016.
  General and Administrative Expenses
  General and administrative
  expenses and related party compensation were $199,964 and $51,228 for the three months ended June 30, 2017 and 2016, respectively.
  Expenses for the three months ended June 30, 2017 consisted primarily $171,166 for professional fees and related party compensation.
  Expenses for the three months ended June 30, 2016 consisted primarily of $50,717 for professional fees.
  27
  Table of Contents
  Interest Expense
  Interest
  expense was $84,989 and $2,699 for the three months ended June 30, 2017 and 2016, respectively, which related to interest
  accrued on borrowings, which were greater in the fiscal period ended June 30, 2017 as a result of newly issued debt in during
  October, November and December 2016 and June 2017. Included in interest expense for the three months ended June 30, 2017, was
  also $66,623 of non-cash interest expense related to the amortization of the debt discount.
  Loss on derivative
  The Company recorded
  a net loss on derivative in the amount of $42,903 in the three months ended June 30, 2017. There was no derivative loss during
  the three months ended June 30, 2016.
  Interest Income
  Interest income
  was $2 and $-0- for the three months ended June 30, 2017 and 2016, respectively, which related to interest from bank accounts.
  Nine Months Ended June 30, 2017
  and 2016
  Revenue
  Revenue was $0
  for the nine months ended June 30, 2017 and 2016.
  Cost of Sales
  Cost of sales
  was $0 for the nine months ended June 30, 2017 and 2016.
  General and Administrative Expenses
  General and administrative
  expenses and related party compensation were $3,433,027 and $228,637 for the nine months ended June 30, 2017 and 2016, respectively.
  Expenses for the nine months ended June 30, 2017 consisted primarily of $2,500,000 of non-cash stock based compensation of Preferred
  B shares regarding the GrandTex acquisition, $836,773 for professional fees and related party compensation. Expenses for the nine
  months ended June 30, 2016 consisted primarily of $216,068 for professional fees which included $43,098 of non-cash stock-based
  compensation expense and $60,000 for investor relations expense.
  Interest Expense
  Interest expense
  was $204,583 and $6,991 for the nine months ended June 30, 2017 and 2016, respectively, which related to interest accrued on borrowings,
  which were greater in the fiscal period ended June 30, 2017 as a result of newly issued debt in during October, November and December
  2016 and June 2017. Included in interest expense for the nine months ended June 30, 2017, was also $159,173 of non-cash interest
  expense related to the amortization of the debt discount.
  Loss on derivative
  The Company recorded
  a net loss on derivative in the amount of $39,579 in the nine months ended June 30, 2017. There was no derivative loss during the
  nine months ended June 30, 2016.
  Interest Income
  Interest income
  was $667 and $-0- for the nine months ended June 30, 2017 and 2016, respectively, which related to interest due on notes receivable
  and interest earned in bank accounts, which were greater in the fiscal period ended June 30, 2017 as a result of the two notes
  receivable issued.
  28
  Table of Contents
  Liquidity and Capital Resources
  The following
  is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities for the nine months
  ended June 30, 2017 and 2016:
  2017
  2016
  Operating Activities
  $
  (669,810
  )
  $
  (20,260
  )
  Investing Activities
  —
  (56,400
  )
  Financing Activities
  763,000
  74,500
  Net Effect on Cash
  $
  93,190
  $
  (2,160
  )
  Since acquiring
  the business plan and website, most of our resources and work have been devoted to our online marketplace and community portal,
  that is, planning our business, web site development, mobile application development, and implementing systems and controls. However,
  this has been suspended for the time being. When those procedures are completed, which we believe will occur over several month
  period following the receipt of adequate financing, we will primarily work on our intended service offerings as well further internal
  development of software for which we have developed our initial framework of and completed some coding. We believe that the work
  needed to initiate and complete the software development for our online marketplace and community portal, attract developers, and
  initiate our marketing plans, including the development of a saleable product suite, may be in excess of $100,000 if outside contractors
  and experts are used. If we are able to secure funding to outsource these procedures, of which there are no assurances, we will
  then commence the launch of our intended services and software products to the public. If we are able to use internal resources
  only (primarily consisting of the services of our president and chief financial officer), the process will take much longer and
  our initial launch may be limited to a much smaller target market. If we are unable to raise any funds from third party sources,
  the development costs would have to be funded by (i) Mr. Brian Loiselle, to whom we issued three notes for funds totaling $74,500,
  or (ii) our president and chief financial officer to the extent that they are capable and willing to provide such funds. While
  we have previously engaged the services of an established software development firm which we used on an as "needed basis",
  their involvement is limited by our ability to raise financing. Our goal would be to have software products available, services
  available, multiple sales channels and a comprehensive corporate website up and running within one year after receipt of adequate
  financing, but there is no way of estimating what the likelihood of achieving that goal would be.
  In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 21,750,000 shares of our common stock to its founder,
  Derek Cahill, as consideration for the purchase of a business plan along with a website. The acquisition of the business plan and
  website was valued at $72,500. To date, we have sold 5,400,000 shares of our common stock at $0.003 per share for $18,000 through
  a private placement and we sold 1,735,800 shares of our common stock at $0.042 per share for total gross proceeds of $72,325 through
  a public placement.
  If a market for
  our shares ever develops, of which there can be no assurances, we may continue to use restricted shares of our common stock or
  stock options to compensate employees/consultants and independent contractors wherever possible. We cannot predict the likelihood
  or source of raising capital or funds that may be needed to complete the development of our business plan and its stages as outlined
  above.
  As a public company,
  we will incur ongoing expenses associated with professional fees for accounting, legal and a host of other expenses including annual
  reports and proxy statements, if required. We estimate that these costs will range up to $50,000 per year over the next few years
  and may be significantly higher if our business volume and transactional activity increases, and we would not be subject to the
  requirements of Section 404 of the Sarbanes-Oxley Act of 2002 for an opinion on our system on internal controls by our independent
  audit firm unless and until we exceed $75 million in market capitalization. These obligations may reduce our ability and resources
  to expand our business plan and activities. We hope to be able to use our status as a public company to increase our ability to
  use noncash means of settling outstanding obligations (i.e. issuance of restricted shares of our common stock) and compensate independent
  contractors who provide professional services to us, although there can be no assurances that we will be successful in any of these
  efforts. We will also reduce compensation levels paid to management (if we attract or retain outside personnel to perform this
  function) if there is insufficient cash generated from operations to satisfy these costs.
  29
  Table of Contents
  We are presently
  seeking equity and debt financing for both segments of our business. However, these actions, if successful, could result in dilution
  of the ownership interests of existing shareholders and further dilute common stock book value, and such dilution may be material.
  The Company may offer shares of its common stock to settle a portion of the professional fees incurred in connection with its registration
  statement. No negotiations have taken place with any professional and no assurances can be made as to the likelihood that any professional
  will accept shares in settlement of obligations due them.
  As of June 30,
  2017, we owed $544,075 in accounts payable, accrued expenses and to related parties, a substantial portion of which are past due.
  The only formal agreements, written or oral, with any vendors or other providers for payment of services or expenses are with respect
  to (i) contracted investor relation services, (ii) contracted services of the Company's former chief operating officer and (iii)
  compensation to the Company's president and chief financial officer and a consultant, one of whom is a director. There are no other
  significant liabilities at June 30, 2017.
  As of June 30,
  2017, the Company had one note payable issued and outstanding with a total principle of $25,000 and accrued interest of $14,400.
  The note was due on June 30, 2015, and has an interest rate of 12%. The note remains unpaid and is in default as of June 30, 2017.
  As of June 30,
  2017, the Company had three notes payable issued and outstanding with a former related party with a total principle of $74,500
  and accrued interest of $10,611. The three notes are due on the earlier of one week after the closing of a certain contemplated
  farm property acquisition or July 31, 2016, and have an interest rate of 10%. The related party for all three notes is East West
  Secured Developments, LLC, an Arizona Limited Liability Company ("EWSD") of which Mr. Brian Loiselle is a managing
  member. On June 30, 2016, the Company entered into Amendment #1 to these three notes to extend the due date to the earlier of one
  week after the closing of the contemplated farm property acquisition or October 31, 2016. The acquisition of the various farm properties
  offered by Mr. Loiselle never occurred, and on August 26, 2016 Mr. Loiselle was notified that his relationship with the Company
  was terminated. Following that notice EWSD made a demand in October 2016 for repayment of the subject loans and subsequently declared
  the notes in default. The default interest demand of 18% by Mr. Loiselle is being disputed by the Company due to the lack of provision
  for default interest in the notes.
  As of June 30,
  2017, the Company had twenty convertible notes payable issued and outstanding with a total principle of $863,025 and accrued interest
  of $43,284. The notes are due December 31, 2017 through December 22, 2019 and have interest rates of 8% to 12%. The notes remain
  unpaid as of June 30, 2017.
  Letters of Intent
  On
  April 24, 2015, the Company signed a non-binding Letter of Intent ("LOI") with a licensed cultivator to provide turnkey
  operations and services to a 150,000-square foot licensed cultivation facility located in Pueblo, Colorado (the "Tamarack
  Project"). In connection therewith, the first phase of construction was expected to begin in June 2015, with cultivation expected
  begin in early July; however, none of these events have occurred as of the filing of this Annual Report on Form 10-K. Further progress
  with respect to this LOI was dependent on, among other matters, the Company obtaining the necessary financing to proceed. The promised
  financing did not materialize and, consequently, we officially terminate all Letters of Intent related to the Tamarack Project
  and a related proposed business venture with Generex Biotechnology Corporation.
  On
  September 13, 2016, we entered into a Letter of Intent with GandTex, the owner of patents covering new techniques for organ transplants
  and tissue repair. We entered into a definitive agreement with GandTex on October 3, 2016 and received assignments related to two
  (2) of the three (3) patents on November 30, 2016
  30
  Table of Contents
  CRITICAL ACCOUNTING PRONOUNCEMENTS
  Our financial statements
  and related public financial information are based on the application of generally accepted accounting principles in the United
  States ("GAAP"). GAAP requires the use of estimates, assumptions, judgments and subjective interpretations of accounting
  principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also
  affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial
  condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively
  applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under
  the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We
  continue to monitor significant estimates made during the preparation of our financial statements.
  Our significant
  accounting policies are summarized in Note 2 of our financial statements included in our September 30, 2016 Form 10-K. While all
  of these significant accounting policies impact our financial condition and results of operations, we view certain of these policies
  as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements
  and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management
  believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies
  would cause a material effect on our results of operations, financial position or liquidity for the periods presented in this
  report.
  Revenue Recognition
  We recognize revenue on arrangements
  in accordance with FASB ASC No. 605, "Revenue Recognition".  In all cases, revenue is recognized only when
  the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability
  of the resulting receivable is reasonably assured.
  RECENT ACCOUNTING PRONOUNCEMENTS
  We have reviewed accounting pronouncements
  issued during the past two years and have adopted any that are applicable to the Company. We have determined that none had a material
  impact on our financial position, results of operations, or cash flows for the periods presented in this report.
  OFF-BALANCE SHEET ARRANGEMENTS
  We do not have any off-balance sheet
  arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as "special purpose
  entities" ("SPE"s).
  Item 3. Quantitative and
  Qualitative Disclosures about Market Risks
  Not applicable because we are a smaller
  reporting company.
  Item 4. Controls
  and Procedures
  Evaluation of Disclosure Controls
  and Procedures
  Pursuant to Rule 13a-15(b) under the
  Securities Exchange Act of 1934 ("Exchange Act"), the Company carried out an evaluation, with the participation of
  the Company's management, including the Company's President (the "President") and principal Financial Officer,
  of the effectiveness of the Company's disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange
  Act) as of the end of the period covered by this report. Based upon that evaluation, the Company's President and principal
  financial officer concluded that the Company's disclosure controls and procedures were not effective to ensure that information
  required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed,
  31
  Table of Contents
  summarized and reported, within the
  time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's
  management, including the Company's President and principal financial officer, as appropriate, to allow timely decisions
  regarding required disclosure as a result of continuing material weaknesses (such as the absence of an audit committee and absence
  of qualified independent directors) in its internal control over financial reporting.
  Changes in Internal Controls Over
  Financial Reporting
  There have been no changes in the Company's
  internal control over financial reporting during the latest fiscal quarter that have materially affected, or are reasonably likely
  to materially affect, the Company's internal control over financial reporting.
  32
  Table of Contents
  PART II - OTHER INFORMATION
  Item 1. Legal Proceedings.
  The Company owes
  on promissory notes that have an aggregate principal amount of $74,500 and are simple promissory notes with 10% annual interest
  to EWSD. The notes are in default, but there is not a default interest provided in the notes. Therefore, the notes continue to
  accrue interest at 10% per annum until paid or collected. Mr. Loiselle is demanding 18% per month interest for the past four months
  to the present. The Company has disputed this interest that is not detailed on the notes. Furthermore, Mr. Loiselle is claiming
  unpaid compensation of $10,000 per month for services without an agreement with the Company. These charges are also being disputed
  by the Company. These disputes represent a material risk, and may be litigated in the future other than the aforementioned, the
  Company currently has no other litigation pending, threatened or contemplated, or unsatisfied judgments.
  From time to time,
  we are also a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our
  rights under contracts with contractors and suppliers. While the outcome of these legal proceedings cannot at this time be predicted
  with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of
  operations.
  Item 1A. Risk Factors
  Not applicable because we are a smaller
  reporting company.
  Item 2. Unregistered Sales of Equity
  Securities and Use of Proceeds
  In October 2013,
  following the Company's incorporation on October 15, 2013, the Company issued 7,250,00 shares of our common, now 21,750,000 shares
  following the 3:1 forward stock split, stock to its founder, Derek Cahill, as consideration for the purchase of a business plan
  along with a website. The acquisition of the business plan and website was valued at $72,500.
  On October 29, 2013,
  the Company completed a private placement whereby it issued 5,400,000 shares of common stock to accredited investors at $0.003
  per share for total gross proceeds of $18,000.
  On April 16, 2014,
  the Company completed a public offering whereby it issued 1,735,800 shares of common stock at $0.042 per share for total gross
  proceeds of $72,325. The Company's Registration Statement on Form S-1 was declared effective March 6, 2014.
  On August 7, 2015,
  the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of the grant, the shares
  were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
  vest over a six-month period, with the vested shares recorded on the accompanying balance sheet under equity - shares to be issued.
  The subject 100,000 shares of common stock will be issued in a subsequent period.
  The Company amended
  and restated that certain outstanding promissory note of the Company, dated July 3, 2015, and in the principal amount of $50,025
  (the "Default Note"). The replacement convertible promissory note (the "Exchange Note") matures on December
  31, 2017 (the "Maturity Date"), and bears interest at the rate of 8% per annum, and the principal and interest due
  thereunder may be prepaid at any time. The Exchange Note, together with all interest as accrued, is convertible into shares of
  the Company's common stock at $0.11, which amount represents the average trailing average high closing Ask price of the Company's
  common stock as of the date of issuance of the Exchange Note.
  On September 2,
  2016, the Company entered into those certain Note Purchase Agreements (collectively, the "Purchase Agreements") in
  connection with the issuance of certain convertible promissory notes (collectively, the "Purchase Notes") in the aggregate
  principal amount of $50,000. All of the Purchase Notes mature thirty-six months from the date of issuance (the "Maturity
  Date"), and bear interest at the rate of 10% per annum. Each of the Purchase Notes may be prepaid until the Maturity Date
  at 110% of the principal and interest amount outstanding. The Purchase Notes, together with all interest as accrued, are each convertible
  into shares of the Company's common stock at 50% of the trailing average highest closing bid price of the Company's
  common stock on the date of conversion. The Purchase Agreements and the Purchase Notes contain representations, warranties, conditions,
  restrictions, and covenants of the Company that are customary in such transactions with smaller companies.
  33
  Table of Contents
  Also on September
  2, 2016, the Company amended and restated the Default Note. The Exchange Note matures on December 31, 2017, and bears interest
  at the rate of 8% per annum, and the principal and interest due thereunder may be prepaid at any time. The Exchange Note, together
  with all interest as accrued, is convertible into shares of the Company's common stock at $0.11, which amount represents
  the average trailing average high closing Ask price of the Company's common stock as of the date of issuance of the Exchange
  Note.
  The Purchase Notes
  may be accelerated by the holders thereof in the event of default. In addition, the amounts due and payable under the Purchase
  Notes (and, consequently, the number of shares of common stock convertible thereunto) may be increased to 150% of the principal
  and interest amounts of the Purchase Notes. The Purchase Notes are a direct financial obligation of the Company and are considered
  a current liability of the Company for accounting purposes.
  We relied upon Section
  4(2) of the Securities Act of 1933, as amended for the above private placement issuances. We believed that Section 4(2) was available
  because:
  •	None of
  these issuances involved underwriters, underwriting discounts or commissions
  •	We placed
  restrictive legends on all certificates issued
  •	No sales
  were made by general solicitation or advertising
  •	Sales were
  made only to accredited investors
  In connection with
  the above transactions, we provided the following to all investors:
  •	Access to
  all our books and records
  •	Access to
  all material contracts and documents relating to our operation
  •	The opportunity
  to obtain any additional information, to the extent we possessed such information, necessary to verify the accuracy of the information
  to which the investors were given access.
  Pursuant
  to the terms of the Asset Purchase Agreement with GandTex, on December 30, 2016 the Board approved the issuance of 10,000,000 shares
  of the Company's Series B Convertible Preferred Stock to GandTex. The shares were released to GandTex concurrent with the
  closing on January 29, 2017.
  On
  January 20 , 2017, the Company entered into a Debt Conversion Agreement (the "Conversion Agreement") in respect of
  $13,750 of the accruing monthly fees due to MZHCI, LLC("MZ") by the Company pursuant to the Investor Relations Consulting
  Agreement between MZ and the Company dated April 1, 2015 (the "Debt") together with a release by MZ in favor of the
  Company for any claims for reimbursement of any and all due diligence expenses, investigative costs or any other type of fees or
  costs incurred by MZ related to the recent purchase by the Company of the GandTex Assets. Pursuant to the terms of the Conversion
  Agreement, the Company issued to MZ an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.
  On
  February 28, 2017 the Company entered into an Advisory Agreement with Global Business Strategies Inc.("Global"), a
  Company owned by the Company's President Fred G. Luke ("the "Global Agreement"), pursuant to which the
  Company retained Global to provide management advice and corporate development strategies, and to make Mr. Luke available to serve
  as the Company's President, for an aggregate of $8,500 per month and, subject to the condition that Global effected filing
  of the Company's its Quarterly Report for the period ending December 31, 2016 on Form 10-Q on a timely basis, Global received
  an aggregate of 55,000 shares of restricted Series A Convertible Preferred Stock.
  On
  June 26, 2017, the Company entered into a Securities Purchase Agreement ("June SPA") in connection with the issuance
  of a convertible promissory note ("June Note") in the aggregate principal amount of $78,000. The June Note matures
  on June 30, 2018 (the "Maturity Date"), and bears interest at the rate of 12% per annum. After 180 days, the June Note
  may not be prepaid. Any amount of principal or interest on the June Note which is not paid when due shall bear interest at the
  rate of twenty two percent (22%) per annum from the due date. The June Note, together with all interest as accrued, is convertible
  into shares of the Company's common stock at a 35% discount to
  34
  Table of Contents
  the lowest
  trading price in the 10-day period ending on the latest complete Trading Day prior to the Conversion Date. The June SPA and the
  June Note contain representations, warranties, conditions, restrictions, and covenants of the Company that are customary in such
  transactions with smaller companies, and the SPA and June Note were attached as Exhibits to our Form 8-K filed on July 27, 2017.
  Item 3. Defaults Upon Senior Securities.
  None
  Item 4. Mine Safety Disclosures
  Not Applicable.
  Item 5. Other Information.
  None.
  35
  Table of Contents
  Item 6. Exhibits.
  Exhibit No.
  Description
  3.1
  Articles of Incorporation(1)
  3.2
  Bylaws(1)
  31.1
  Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.1
  Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  101.INS
  XBRL Instance Document
  101.SCH
  XBRL Taxonomy Extension Schema Document
  101.CAL
  XBRL Taxonomy Extension Calculation Linkbase Document
  101.DEF
  XBRL Taxonomy Extension Definition Linkbase Document
  101.LAB
  XBRL Taxonomy Extension Label Linkbase Document
  101.PRE
  XBRL Taxonomy Extension Presentation Linkbase Document
  (1) Incorporated herein by reference to the Company's Form 10-Q filed with the Securities and Exchange Commission
  on February 21, 2017.
  SIGNATURES
  Pursuant to the requirements of the
  Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
  duly authorized.
  NuLife Sciences, Inc.
  Date:
      August 14, 2017
  By:
  /s/  Fred Luke
  Fred Luke
  President
  (Duly Authorized Officer and Principal Executive Officer)
  36